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Summary 
 
Medulloblastoma (MB) is the most common malignant brain tumor of childhood that 
comprises at least four molecularly distinct subgroups. One subgroup is characterized by 
aberrant Sonic hedgehog (SHH) signalling. Despite the ubiquitous activation of the SHH 
pathway within this subgroup, there is clear evidence that tumors with a SHH profile may 
vary in certain molecular and clinical aspects. Targeted therapies as a novel treatment 
modality for MB patients are especially intriguing for primary and relapsed SHH-MB. As 
more drugs targeting the Hh pathway become available and enter clinical trials, it is 
important to know how to stratify the patients for different drugs in order to maximize 
response rates and to prevent unnecessary treatment failures. 
In a first project, we aimed to characterize tumor localization in murine Shh-associated 
models. Using well established mouse models we show here that oncogenic 
transformation of cerebellar granule cell precursors at early developmental time points 
may result in the formation of midline and hemispheric medulloblastoma. On the other 
side, oncogenic transformation at later developmental time points exclusively results in 
the formation of hemispheric medulloblastoma. These data, which perfectly match to the 
recently published observations in human patients, indicate that granule neuron 
precursors are biologically distinct in different cerebellar compartments and that 
localization of SHH medulloblastoma is dependent on the time rather than the kind of 
genetic alteration. 
In a second project, we aimed to investigate the effect of the Wnt pathway on Shh-
associated medulloblastoma. Previous studies were able to show that Wnt/ß-Catenin 
activation might be able to inhibit Shh-associated medulloblastoma growth through 
downregulation of the Shh pathway. Considering a possible therapeutic approach, in vitro 
treatments with lithium chloride, a well-known Wnt/ß-Catenin agonist, were carried out. 
Lithium chloride treatment in vitro resulted in a decrease of granule neuron precursor 
and tumor cell viability. 
In the third project, we aimed to better understand the mechanisms in MB of primary and 
secondary resistance to drugs targeting the Hh pathway. To this end, we generated new 
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mouse models, characterized and used these and already existing genetically engineered 
mouse models (GEMMs). We aimed to further expand our pre-existing repertoire of 
murine SHH-activated MB models in order to have a spectrum of tumors that are driven 
by mutations at different levels of the Hh pathway, such as PTCH1, SMO, or MYCN, and 
with different combinations of other mutations in additional pathways that may co-
operate with HH signalling (e.g. TP53 or PIK3CA). The mouse strains Math1-creERT2::lsl-
SmoM2Fl/+, Math1-creERT2::lsl-SmoM2Fl/+ lsl-Pik3caFl/+, Math1-creERT2::Ptch1Fl/Fl,  Math1-
creERT2::Ptch1Fl/Fl lsl-Pik3caFl/+, and Math1-creERT2::Ptch1Fl/Fl lsl-Pik3caFl/Fl developed Shh-
associated medulloblastoma. Our mouse model with a MYCN mutation did not develop 
any tumor, neither as such nor with an additional TP53 mutation. Math1-creERT2::lsl-
SmoM2Fl/+, Math1-creERT2::lsl-SmoM2Fl/+ lsl-Pik3caFl/+, and Math1-creERT2::Ptch1Fl/Fl mice 
were then treated with the SMO inhibitor LDE225, that is already used in clinical trials. 
Math1-creERT2::lsl-SmoM2Fl/+ and Math1-creERT2::Ptch1Fl/Fl mice first benefit from the 
treatment, but then also die due to symptoms of the tumor, whereas Math1-creERT2::lsl-
SmoM2Fl/+ lsl-Pik3caFl/+ mice did not show a better prognosis for survival at all. None the 
less, proliferation was reduced in all tumors treated with LDE225.  
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Zusammenfassung 
 
Das Medulloblastom (MB) ist ein maligner Hirntumor, welcher vornehmlich im 
Kindesalter auftritt und in der hinteren Schädelgrube mit starkem Bezug zum Kleinhirn 
entsteht. Basierend auf variierenden globalen Expressionsprofilen wird das humane 
Medulloblastom in vier verschiedene molekulare Subgruppen eingeteilt. Während eine 
dieser Subgruppen durch eine pathologische Aktivierung des Sonic hedgehog (SHH)-
Signalwegs charakterisiert ist, weisen trotz dieser Gemeinsamkeit auch die Tumore 
innerhalb dieser Subgruppe ein beträchtliches Maß an Heterogenität bezüglich 
molekularer und klinischer Parameter auf. Gezielte Therapien als neuartige 
Behandlungsmethode für MB-Patienten sind besonders faszinierend für primäre und 
rezidivierende SHH-MB. Da mehr Medikamente verfügbar sind, die auf den HH-Signalweg 
abzielen, und in klinischen Studien eingehen, ist es wichtig zu wissen, wie man die 
Patienten für verschiedene Medikamente stratifiziert, um die Ansprechrate zu 
maximieren und unnötige Behandlungsfehler zu vermeiden. 
In einem ersten Teilprojekt sollte die Tumorlokalisation in murinen Shh-assoziierten 
Modellen charakterisiert werden. Unter Verwendung gut etablierter Mausmodelle 
konnten wir hier zeigen, dass die onkogene Transformation von cerebellären 
Körnerzellvorläufern zu frühen Entwicklungszeitpunkten zur Bildung von 
Medulloblastomen in der Mittellinie und in den Hemisphären führen kann. Auf der 
anderen Seite führt die onkogene Transformation zu späteren Entwicklungszeitpunkten 
ausschließlich zur Bildung von Medulloblastomen in den Hemisphären. Diese Daten, die 
perfekt zu den kürzlich veröffentlichten Beobachtungen bei menschlichen Patienten 
passen, deuten darauf hin, dass Körnerzellvorläufer in verschiedenen cerebellären 
Kompartimenten biologisch verschieden sind und, dass die Lokalisation von SHH-
Medulloblastomen von der Zeit abhängt und nicht von der Art der genetischen 
Veränderung. 
In einem zweiten Teilprojekt sollte der Effekt des Wnt-Signalwegs auf Shh-assoziierte 
Medulloblastome untersucht werden. Frühere Studien konnten zeigen, dass die Wnt/ß-
Catenin-Aktivierung in der Lage sein könnte das Wachstum von Shh-assoziierten 
Medulloblastomen durch die Herunterregulation des Shh-Signalweges zu hemmen. In 
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Anbetracht eines möglichen therapeutischen Ansatzes wurden in vitro Behandlungen mit 
Lithiumchlorid, einem bekannten Wnt/ß-Catenin-Agonisten durchgeführt. Die 
Lithiumchloridbehandlung in vitro führte zu einer Verringerung der Lebensfähigkeit von 
Körnerzellvorläufern und Tumorzellen. 
Im dritten Teilprojekt zielten wir darauf ab, die Mechanismen von Medulloblastomen mit 
primären und sekundären Resistenzen gegenüber Substanzen, die gegen den Hh-
Signalweg gerichtet sind, besser zu verstehen. Dazu wurden neue Mausmodelle erstellt 
und charakterisiert, und diese und bereits vorhandene gentechnisch hergestellte 
Mausmodelle (GEMMs) genutzt. Das bereits vorhandene Repertoire an murinen SHH-
aktivierten MB-Modellen sollte weiter ausgebaut werden, um ein Spektrum von Tumoren 
zu erhalten, mit Mutationen, die auf verschiedenen Ebenen des HH-Signalweges, wie 
PTCH1, SMO oder MYCN basieren, und mit verschiedenen Kombinationen anderer 
Mutationen von zusätzlichen Signalwegen, die mit dem HH-Signalweg kooperieren (z.B. 
TP53 oder PIK3CA). Die Mauslinien Math1-creERT2::lsl-SmoM2Fl/+, Math1-creERT2::lsl-
SmoM2Fl/+ lsl-Pik3caFl/+, Math1-creERT2::Ptch1Fl/Fl,  Math1-creERT2::Ptch1Fl/Fl lsl-Pik3caFl/+, 
und Math1-creERT2::Ptch1Fl/Fl lsl-Pik3caFl/Fl entwickelten Shh-assoziierte 
Medulloblastome. Unser Mausmodell mit einer MYCN Mutation entwickelte keine 
Tumoren, auch nicht mit einer zusätzlichen TP53 Mutation. Math1-creERT2::lsl-SmoM2Fl/+, 
Math1-creERT2::lsl-SmoM2Fl/+ lsl-Pik3caFl/+, und Math1-creERT2::Ptch1Fl/Fl Mäuse wurden 
anschließend mit dem Smo-Inhibitor LDE225 behandelt, der bereits in klinischen Studien 
genutzt wird. Math1-creERT2::lsl-SmoM2Fl/+ und Math1-creERT2::Ptch1Fl/Fl Mäuse 
profitieren zuerst von der Behandlung, sterben aber letztendlich an Symptomen des 
Tumors, wohingegen Math1-creERT2::lsl-SmoM2Fl/+ lsl-Pik3caFl/+ Mäuse überhaupt keine 
bessere Überlebensprognose aufweisen. Trotzdem wurde die Proliferation in allen mit 
LDE225 behandelten Tumoren reduziert.  
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1 Introduction 
1.1 Function and structure of the cerebellum 
 
The cerebellum is part of the motoric system. It receives sensory information of the brain 
stem and the spinal cord. The cerebellum on its own is not able to initiate movements, but 
is responsible for coordination and fine adjustment of course of motions. In this context 
it is responsible for back-up motor apparatus of posture and movement, the motor 
activity and eye movement controlled of the cerebrum. In addition, it controls the muscle 
tone and maintains the balance. 
The cerebellum lies in the posterior fossa dorsal to the brain stem (Mesencephalon, Pons, 
Medulla oblongata). Between the cerebellum and the brain stem lies the fourth ventricle 
filled with cerebrospinal fluid (CSF). The three cerebellar peduncles (Pedunculus 
cerebellaris superior, medius, inferior) connect the cerebellum with the brain stem and 
contain afferent as well as efferent fibres. The structuring of the cerebellum in the 
cerebellar vermis (Vermis cerebelli) and both lateral hemispheres (Hemispheria cerebelli) 
are clearly visible. The whole cerebellum contains a fine surface structure which consists 
of fissures (Fissurae cerebelli) and foliage (Folia cerebelli). As well as in the cerebrum 
(Telencephalon), the outward lying structure which is rich of neurons is the cortex (Cortex 
cerebelli) and the inner lying white substance with many fibres is the central white matter 
of the cerebellum (Corpus medullare cerebelli). 
The adult cerebellar cortex is subdivided into three layers: the molecular layer (ML), the 
purkinje cell layer (PCL) and the inner granule cell layer (IGL) (Figure 1). Here the ML 
mainly consists of basket and stellar cells, the PCL consists of purkinje cells and Bergman 
glia cells and the IGL consist of mature granule cells, golgi cells, and astrocytes. The white 
matter with nerve cell fibres, astrocytes, and oligodendrocytes and the deep cerebellar 
nuclei complete the structure of the cerebellum (Altmann 1997).  
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Figure 1 Sketch of the structure and cytoarchitecture of the cerebellar cortex. Sagittal and frontal section of 
a cerebellar folium with relevant cell types and fibers of the cerebellum ((Purves 2004); Purves et al: 
Neuroscience, Third Edition; with permission of Sinauer Associates). 
 
1.2 Development of the cerebellum 
 
The cells of the central nervous system (CNS) can be broadly divided into glial cells and 
neuronal cells, both differentiate from multipotential neural progenitor cells (Edlund and 
Jessell 1999). 
The cerebellar granule neuron is by far the most common cell type in the adult cerebellum 
and forms the innermost granule layer. The following Purkinje cell layer is a monolayer 
of fan-shaped Purkinje neurons with dendritic arborisation (Palay and Chan-Palay 1974). 
The cell bodies of the Bergmann glia lie in the region of the cell bodies of Purkinje cells 
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and their fibres pass the outermost molecular layer to the pial surface (Grosche et al. 
2002, Welsch 2006). In addition to the Bergmann glial fibres also the processes of the 
cerebellar granule neurons, the parallel fibres, and the dendritic arborisation of the 
Purkinje cells extend into the molecular layer. 
The development of the cerebellum in mice starts around embryonic day 9 (E9) with the 
development of the cerebellar anlage and finishes around postnatal day 20 (P20) (Hatten 
and Heintz 1995). Here the cerebellum descends from rhombomer r1, the rostral part of 
the rhombic lip, which is confined by the expression of the transcription factors Otx2 and 
Hoxa2 and is called the upper rhombic lip (Joyner 1996, Wingate and Hatten 1999, Joyner 
et al. 2000). The rhombomers r2-r8 form in their entirety the lower rhombic lip 
(Landsberg et al. 2005). In detail, all cells of the cerebellum stem from two different 
germinal epithelia. Purkinje cells, cells of the deep cerebellar nuclei and more than 6 
different kinds of inhibitory interneurons like e.g. Golgi-, basket- and stellar- cells stem 
from the dorso-medial ventricular zone along the IV. ventricle (Hallonet and Le Douarin 
1993, Dino et al. 2000, Hoshino et al. 2005). The second germinal epithelium, the rhombic 
lip, is the point of origin of the cerebellar granule cells as well as of a subpopulation of the 
deep cerebellar nuclei and neurons of different pre-cerebellar nuclei in the brain stem 
(Wingate and Hatten 1999, Wingate 2001, Machold and Fishell 2005, Wang et al. 2005). 
In detail, the development of the cerebellum starts, as in all chordates, with neurulation, 
the development of the neural tube, as basis for the later central nervous system (CNS). 
Of the three embryonic germ layers (endoderm, mesoderm and ectoderm) only the 
central part of the ectoderm contributes to the development of the neural plate and the 
following folding of the neural tube. The unfolding happens at the neural plate by the 
development of the neural groove and the dorsal closing to a tubular structure, which 
represents the early spinal cord. In the inside of the neural tube is the Liquor 
cerebrospinalis, which holds the cavity open for the proper formation of the brain. The 
neurulation is induced by soluble growth factors of the notochord and the roof plate, 
which cause a compartmentalization of the embryonic CNS by dorso-ventral gradients of 
BMP-4 (bone morphogenetic protein 4) and SHH (sonic hedgehog) (Watanabe et al. 
1998). The cerebellar primordium develops out of a gap in the dorsal neural tube, which 
leads to a lateral protrusion on the level of the pontine bend. The dorso-lateral regions of 
the wing plate bend medially and build up the rhombic lip (RL). Through growth 
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movement and protrusion of the rhombic lip to dorsal, a transversal placed plate is 
formed, the neural plate (Duband 2010). The rhombic lip is one of the both germinal zones 
of the developing cerebellum. Here granule cell precursors originate. Purkinje cells, as an 
example for cells of the ventricular zone, proliferate in their germinal zone only between 
embryonic day 11–14 (E11-E14). As these cells migrate radial in the developing 
cerebellum after they left the cell cycle, granule cell precursors migrate out of the upper 
rhombic lip, starting at E13–E15, tangential through the surface of the cerebellar anlage 
and there build up a secondary proliferation zone, the external granule cell layer (EGL) 
(Hatten and Heintz 1995, Hatten et al. 1997). The mitogen sonic hedgehog (Shh), which is 
generated by the purkinje cells, leads to a massive expansion of the granule cell 
population (Wechsler-Reya and Scott 1999). Here the EGL can be subdivided into a 
superficial zone of proliferating cells and an inner zone of differentiating cells. This 
subdivision is evident by the expression of different marker genes (RU-49, NeuN, etc.), 
which are differentially expressed during cerebellar development (Hatten and Heintz 
1995, Weyer and Schilling 2003). The localization of these marker genes has shown that 
the development of cerebellar granule cells can be subdivided into at least 4 phases: 
neurogenesis, differentiation, migration and generation of synaptic connections. After 
they have left the cell cycle, granule cells migrate radially along the extensions of the 
Bergman glia cells into the cerebellum and there form the internal granule cell layer (IGL) 
(Rakic and Sidman 1973).  
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1.3 Medulloblastoma 
 
Medulloblastoma (MB) is the most common malignant brain tumor in children. Current 
treatments for MB include surgical resection followed by irradiation of the entire neuraxis 
and high-dose chemotherapy. Many patients die despite these treatments, and those who 
survive often suffer from cognitive deficits and endocrine disorders as a consequence of 
therapy (Mulhern et al. 2005). 
 
1.3.1 Classification of medulloblastoma 
 
Since 2016 the World Health Organization (WHO) classifies MB based on histology and 
also molecular features (Louis et al. 2016). For histology several subtypes of the disease 
are recognized: classic, large cell/anaplastic (LCA), nodular/desmoplastic and MB with 
extensive nodularity (Louis et al. 2007). Patients with nodular/desmoplastic histology 
tend to have favourable outcomes, while those with large cell and anaplastic (LCA) 
histology have the worst prognosis (Eberhart et al. 2002, McManamy et al. 2007). Recent 
advances in microarray and genomic sequencing technologies have enabled a deeper 
understanding of MB. Based on such analysis, MBs have now been divided into 4 major 
molecular subgroups: WNT, Sonic Hedgehog (SHH), Group 3 and Group 4 (Jones et al. 
2012, Northcott et al. 2012, Pugh et al. 2012, Robinson et al. 2012, Taylor et al. 2012). The 
WNT- and the SHH-subgroup are characterized by a constitutive activation of different, 
highly conserved signalling pathways (WNT- and SHH-signalling) (Figure 2). Since 2016, 
SHH-activated MB are subclassified into a TP53-mutant and a TP53-wildtype group (Louis 
et al. 2016). 
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Figure 2 Comparison of the various subgroups of medulloblastoma including their affiliations with 
previously published papers (with outdated nomenclature of groups) on medulloblastoma molecular 
subgrouping (Taylor et al. 2012; with permission of Springer, copyright (2011), license number 
3967660344265). 
 
The WNT subgroup shows a very good long-term prognosis in comparison to other 
subgroups (Ellison et al. 2005, Clifford et al. 2006, Rogers et al. 2009, Ellison et al. 2011). 
WNT-associated tumors, which occur in children and teenagers as well as in adults, 
normally have disrupted WNT signalling genes, including activating mutations in CTNNB1 
(ß-catenin), which activates canonical WNT signalling, and inactivating mutations in the 
adenomatous polyposis coli (APC) gene, a negative regulator of the WNT pathway 
(Hamilton et al. 1995, Zurawel et al. 1998). Other common features of the WNT subgroup 
are chromosome 6 loss and expression of the WNT-gene DKK1 (Thompson et al. 2006, 
Northcott et al. 2011). WNT MBs typically have classic histology (Rogers et al. 2009). 
Analogous to the WNT subgroup, MBs of the SHH subtype show a characteristic activation 
of the Sonic hedgehog signalling pathway (Kool et al. 2008, Northcott et al. 2011, Schwalbe 
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et al. 2011, Kool et al. 2012). Medulloblastoma of the SHH subtype (about 25% of all MBs) 
are the best analysed subgroup (Hatten and Roussel 2011). Common are somatic 
mutations in genes of this signalling pathway like inactivating mutations in the negative 
regulators PATCHED1 (PTCH1) or Suppressor of Fused (SUFU), activating mutations in 
the signal transducing molecule SMOOTHENED (SMO), but also amplifications of the SHH-
target genes GLI1 and GLI2 transcription factor can lead to the constitutive activation of 
the pathway (Johnson et al. 1996, Hahn et al. 1999, Northcott et al. 2009, Adamson et al. 
2010, Pfister et al. 2010, Northcott et al. 2011, Taylor et al. 2012). Many SHH-associated 
MBs have desmoplastic/nodular histology, although classic and LCA histologies are also 
observed (Taylor et al. 2012). SHH MB occurs in infants, where the prognosis is 
favourable, as well as in adults, where the prognosis is more variable (Kool et al. 2012). 
In this subgroup, there is a special age distribution. Mainly infants and adults develop SHH 
medulloblastoma, children quite rarely (Northcott et al. 2011). This biphasic age 
distribution presumes a huge heterogeneity in clinical, molecular and developmental 
biological parameter in this group. In addition, localization of human SHH MBs differs 
depending on the age of the patient. For so far unknown reasons, adult SHH MBs are 
almost exclusively located in cerebellar hemispheres, whereas infant SHH MBs often grow 
in the vermis (Wefers et al. 2014). It is known that an activation of the SHH pathway in 
granule cell precursors of the rhombic lip and the external granule cell layer (EGL) can 
lead to the development of Shh-associated Medulloblastoma (Schüller et al. 2008). 
Recently, it was shown that SHH-associated MB can also arise from granule neuron 
precursors of the cochlear nucleus of the brainstem (Grammel et al. 2012). 
The majority of MBs do not exhibit activation of the WNT or SHH pathways, and these 
tumors can be divided into at least two subtypes – Group 3 and Group 4 – based on gene 
expression, DNA copy number changes and mutations. Group 3 MB patients commonly 
exhibit amplification or overexpression of the MYC oncogene and have gene signatures 
resembling those of photoreceptors and gamma-aminobutyric acid expressing 
(GABAergic) neurons (Taylor et al. 2012). In contrast, Group 4 tumors often exhibit 
amplification of CDK6 and MYCN or duplication of the Parkinson’s Disease-associated 
gene synuclein alpha interacting protein (SNCAIP), and have expression profiles 
reminiscent of glutamate-expressing (glutamatergic) neurons (Northcott et al. 2012). 
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These four subgroups are highly distinct in tumor histology and biology, and in addition 
show divergent clinical phenotypes such as differences in patient demographics, tumor 
dissemination, and patient outcome (Kool et al. 2012, Northcott et al. 2012, Taylor et al. 
2012). Recently, a large series of pediatric MB was analysed using next generation 
sequencing technologies to map the genomic landscape of MB and to identify novel driver 
mutations in each molecular subgroup (Parsons et al. 2011, Jones et al. 2012, Northcott et 
al. 2012, Northcott et al. 2012, Pugh et al. 2012, Rausch et al. 2012, Robinson et al. 2012). 
As there are still many MB, for which a clear driver mutation is not identified yet, it was 
also analysed the epigenome of a large series of MB using whole genome bisulfite 
sequencing and ChIP-seq for various histone modifications to investigate, to what extent 
epigenetics plays a role in MB tumorigenesis and whether epigenetic alterations may 
explain the formation of tumors, in which a clear driver mutation was not found (point 
mutations, small insertions or deletions or focal copy-number aberrations) by WGS 
(Hovestadt et al. 2014). 
 
1.3.2 Symptoms, diagnostics and therapy of medulloblastoma 
 
First clinical symptoms are typically unspecific symptoms of an increased intracranial 
pressure: head ache, impaired vision, morning sickness and vomiting (Alston et al. 2003). 
Very young patients can develop a hydrocephalus due to the blockade of the circulation 
of the cerebrospinal fluid (CSF). This means that the increased fluid pressure in the 
ventricular system of the whole brain leads to the deformation of the still flexible calvaria. 
The primary localization of the medulloblastoma in the cerebellum causes the increased 
appearing ataxia in the course of the disease. Dizziness and problems with coordination 
as well as a general impairment of motor function are typical for progressive tumor 
growth. Neurological deficits, which are typical for the secondary affected brain 
structures can be observed at infiltrating growth and metastases. Diagnosis is made with 
imaging techniques (magnetic resonance imaging, MRI), where you can evaluate 
localization, size and extent of the tumor. For validation of the diagnosis and for 
therapeutic approach the dissected tumor tissue is examined by histology, 
immunohistochemistry and molecular methods. Independent of the subgroup, the 
treatment consists of a combination of resection, irradiation and chemotherapy (Evans et 
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al. 1990, Tait et al. 1990, Kortmann et al. 2000, Taylor et al. 2003). For very young patients 
you have to balance the chance of success of the irradiation and the psychomotor and 
cognitive disturbances in the early infantile development and the coincided postnatal 
development of the cerebellum (Duffner et al. 1993). Despite of substantial progress, 
actual therapy approaches still show unwanted secondary effects and hence resulting 
significant death rate. Due to the detailed characterisation of the subgroups of 
medulloblastoma and the analysis of the cell of origin of the different subtypes, therapies 
can be fitted to the proteins or cell populations involved. Due to the well-known influence 
of the SHH pathway on the development of medulloblastoma, many low-molecular 
connections were discovered, which can repress the activity of the SHH pathway as 
inhibitors of the transmembrane receptor Smoothened. The efficacy of these inhibitors 
could already be proven in allografts and mouse models for medulloblastoma (Berman et 
al. 2002, Romer et al. 2004, Romer and Curran 2005) and are analysed in clinical studies 
at the moment for the benefit in the human system (Coon et al. 2010). Molecular analyses 
of primary medulloblastoma promise much progress with regard to targeted cancer 
therapies, which have the molecular, cytological and developmental biological 
characteristics of the tumors as basis. 
Targeted therapies as a novel treatment modality for MB patients are especially intriguing 
for primary and relapsed SHH-MB. As more drugs targeting the Hh pathway become 
available and enter clinical trials, it is important to know how to stratify the patients for 
different drugs in order to maximize response rates and to prevent unnecessary 
treatment failures. Current clinical trials targeting SHH-MB with SMO antagonists (such 
as LDE225) use a five-gene signature to identify SHH-MB. However, this signature is not 
sufficient as a predictive biomarker for response to SMO antagonists, since it detects all 
SHH-MB with Hh activation regardless of their underlying genetic makeup (Kool et al. 
2014). Indeed, it is clear from clinical trials using SMO antagonists that the response 
appears to be highly variable with a large proportion of striking durable responders, but 
also with a lot of non-responders. Recent data have shown that SHH-MB are genetically 
very heterogeneous and the response to drugs antagonizing the Hh pathway strongly 
depends on the type of mutation that activates the pathway. To understand the 
mechanism(s) of primary resistance and to identify pathways co-operating with aberrant 
Hh signalling, a large cohort of SHH-MB (n = 133) was sequenced and profiled. Hh 
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pathway mutations identified in this study involved PTCH1 (found across all age groups), 
SUFU (mainly found in infants, including many in the germline), and SMO (mainly in 
adults) (Figure 3). 
 
 
Figure 3 Hh pathway mutations in 133 sequenced SHH-MB. Cases have been split up in infants, children and 
adults, and are sorted based on the type of mutation in the Hh pathway. Results show that SHH-MB are 
genetically heterogeneous and the different age groups harbor different predominant mutations activating 
the Hh pathway (reprinted from with permission of Elsevier (Kool et al. 2014), copyright (2014), license 
number 3967660794571). 
 
Older children harbored an excess of downstream MYCN and GLI2 amplifications and 
frequent TP53 mutations, often in the germline, all of which were exceedingly rare in 
infants and adults.  
 
1.3.2.1 Resistance to SMO inhibition 
 
Functional assays in different patient-derived SHH-MB xenograft models demonstrated 
that SHH-MB harboring a PTCH1 mutation were responsive to SMO inhibition, whereas 
tumors harboring SUFU mutations or MYCN amplifications were primarily resistant. SHH-
MBs with alterations in downstream SHH pathway genes, however, such as SUFU, GLI2, or 
MYCN, demonstrated primary resistance to SMO inhibition (Lee et al. 2007). These data 
showed for the first time that most adults, but only half of the pediatric patients with SHH-
MB will likely be responsive to SMO inhibition as predicted by molecular analysis of the 
primary tumor and tested in the SHH-xenografts. SHH-MB patients resistant to SMO 
inhibitors need to be treated with other inhibitors targeting the pathway, for instance, at 
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the level of GLI. Furthermore, as has been shown in both humans and mice, tumors may 
also rapidly acquire secondary resistance to treatment (Rudin et al. 2009, Yauch et al. 
2009, Dijkgraaf et al. 2011), suggesting that such inhibitors might be ineffective as a 
curative option when administered as monotherapy. It is strongly advocated that the next 
generation of SMO inhibitor trials should be based on underlying tumor genetics because 
many patients with SHH-MB will not respond to these inhibitors. Alternative treatment 
options could include arsenic trioxide (ATO) targeting GLI transcription factors by 
degrading the protein (Kim et al. 2013). ATO and the antifungal agent itraconazole (which 
acts on SMO) have also been suggested in preclinical experiments for use in SHH-MBs that 
become resistant after treatment with SMO antagonists (Kim et al. 2013) or in 
combination with SMO inhibitors upfront knowing that GLI2 amplifications comprise a 
common mechanism of secondary resistance to SMO inhibition in preclinical models 
(Buonamici et al. 2010, Dijkgraaf et al. 2011). Recurrent mutations in additional pathways 
also suggested rational combination therapies including epigenetic modifiers and 
PI3K/AKT inhibitors, especially in adults. Other options for combination therapies to 
avoid or delay the development of resistance include drugs targeting PI3K/AKT/mTOR- 
or PKA-signalling pathways, both mutated in a subset of patients with SHH and both also 
leading to GLI activation (Milenkovic and Scott 2010, Wang et al. 2012, Metcalfe et al. 
2013), or epigenetic drugs. Most MB molecular data have been generated for primary 
resected tumors, but patients usually die of relapses/metastases that do not respond 
anymore to therapy. Therefore, it is of utmost importance to gain insight in the molecular 
alterations that are present in these relapses and/or metastases to improve the survival 
of these relapsed patients. 
 
1.3.3 Altered signalling pathways  
 
The dysregulation of two evolutionary highly conserved signalling pathways can lead to 
disturbances of postnatal development of the cerebellar cortex and to the development of 
medulloblastoma. These pathways are the WNT- and the Sonic hedgehog (SHH)- pathway 
(Figure 4). 
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Figure 4 The WNT and SHH pathway. These two major signalling pathways regulate a wide range of 
developmental events, particularly the proliferation of cerebellar granule cells by sonic hedgehog (SHH). 
Both pathways have been implicated as targets for disruption in childhood solid tumors (CSTs), including 
medulloblastoma, a granule-cell-derived brain tumor. WNT and SHH bind to the cell-surface receptors 
frizzled (FRZ) and patched (PTCH), respectively. Binding of WNT activates its receptor, which then blocks 
the phosphorylation-activated (by glycogen synthase kinase-3ß (GSK3ß) in a complex with APC and axin) 
degradation of ß-catenin (ß-Cat). As a consequence, ß-catenin translocates to the nucleus and activates 
transcriptional events that, in some contexts, promote proliferation. Binding of SHH inhibits PTCH function 
and so releases smoothened (SMO) to activate intracellular events. SMO represses the cleavage of GLI (the 
cleaved form has a transcriptional-repressor role in the nucleus), resulting in its release from a complex 
including fused (FU) and costal (COS). GLI is subsequently translocated to the nucleus and, as a result, 
activates target genes that, in some contexts, produce a pro-proliferative response. So, there is a great deal 
of similarity between these two pathways. Furthermore, suppressor of fused (SUFU) represses both 
pathways by promoting nuclear export of both ß-catenin and GLI. SUFU can also directly repress the 
transcriptional activity of intact GLI. Mutations in SUFU, ß-catenin, PTCH and SMO have all been implicated 
as causative events in medulloblastoma. Black steps are activating and red steps are inhibitory. Large 
arrows indicate movements within the cell, whereas thin arrows represent activating molecular targets. 
Thin T-bars indicate inhibiting molecular targets. DSH, dishevelled; TCF, T-cell factor; GRO, groucho. 
(reprinted by permission from Macmillan Publishers ltd: Nature Reviews Cancer (Scotting et al. 2005), 
copyright (2005), license number 3967661323110) 
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1.3.3.1 The Wnt pathway 
 
The Wnt (Wingless related integration site) pathway is a highly conserved signalling 
pathway, which was first discovered due to its role in carcinogenesis (Nusse and Varmus 
1982) and body axis formation during embryonic development (Klaus and Birchmeier 
2008). 
In the inactive state of the WNT signalling pathway, ß-catenin, which is coded by the gene 
CTNNB, is phosphorylated in the cytoplasma of the cell (Amit et al. 2002). ß-catenin is 
ubiquitinated by a protein complex of APC, Axin, Ck1α and kinase GSK-3ß and thus 
degraded by the proteasomal route of degradation (Aberle et al. 1997, Behrens et al. 1998, 
Itoh et al. 1998). After binding of a WNT-agonist to the transmembrane receptor Frizzled, 
an intracellular signalling cascade leads to the inactivation of the protein kinase GSK-3ß 
whereby ß-catenin is not phosphorylated anymore (Bhanot et al. 1996, Salic et al. 2000). 
Hence ß-catenin can’t be ubiquitinated anymore and therefore is not degraded. In 
consequence, ß-catenin reaches the nucleus where it functions as primary effector of the 
WNT-signalling and leads to the transcription of target genes as Dkk1, MYC, Axin2 and 
CD44 (He et al. 1998, Wielenga et al. 1999, Jho et al. 2002, Chamorro et al. 2005). The WNT 
pathway is pathologically altered in 10-15% of all medulloblastoma cases which led to the 
name of the WNT subgroup due to the characteristic activation (Roussel and Hatten 2011). 
First indications for the involvement of this pathway in the development of 
medulloblastoma were made due to the fact that patients with the Turcot syndrome, 
which is caused by mutations in the tumor suppressor gene APC, tend to develop colon 
carcinoma and neuroepithelial brain tumors including medulloblastoma (Hamilton et al. 
1995, Marino 2005). In addition, sporadic mutations in the CTNNB1 gene can often be 
found in this subgroup, which lead to stabilization of ß-catenin und therefore to the 
activation of the WNT pathway (Zurawel et al. 1998). 
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1.3.3.2 The Sonic hedgehog pathway  
 
In the inactive state of the hedgehog pathway, the transmembrane receptor Patched 
(PTCH1) inhibits the G-protein coupled receptor Smoothened (SMO) which leads to the 
inhibition of the whole signalling pathway. Ligands for the Patched receptor in mammals 
are three different proteins (sonic hedgehog, indian hedgehog, desert hedgehog) 
(Echelard et al. 1993). Through binding of SHH-ligands to the extracellular domain of the 
Patched receptor, the inhibition of Smoothened by Patched is removed and the signal is 
transmitted. Therefore Smoothened migrates into the primary cilium of the cell and 
causes the dissociation of the protein complex consisting of SUFU (Suppressor of fused 
homolog) and the transcription factors Gli2 and Gli3 (Corbit et al. 2005, Huangfu and 
Anderson 2006, Wang et al. 2009). After dissociation of SUFU, the transcriptions factors 
move into the nucleus and there regulate the gene expression (Aza-Blanc et al. 1997, Bai 
et al. 2002). The Sonic hedgehog pathway is significantly involved in the development of 
the cerebellum. During the postnatal development of the cerebellum, granule cell 
precursors move transversally out of the upper rhombic lip over the surface of the 
cerebellum and there build the external granular layer (EGL) (Altmann 1997). Sonic 
hedgehog, which is produced by Purkinje cells serves as growth factor for these granule 
cell precursors and leads to a rapid expansion of this cell population during the postnatal 
development (Hatten 1999, Wechsler-Reya and Scott 1999). In this context it is not 
surprising that mutations in genes of this signalling pathway which is important for the 
proliferation of granule cell precursors were early associated with the development of 
medulloblastoma. Thus, in patients with a germline mutation in the SHH-receptor PTCH1 
the Gorlin-syndrome is manifested which is featured among other things by a 
predisposition for medulloblastoma (Bale et al. 1998, Taylor et al. 2000). In a similar way, 
germline mutations in the SHH-inhibitor SUFU also lead to an increased development of 
medulloblastoma (Taylor et al. 2002, Pastorino et al. 2009, Brugieres et al. 2010). Somatic 
mutations in genes of the SHH pathway like PTCH, SMO and SUFU, but also amplifications 
of the SHH target genes GLI1 and GLI2, were identified in sporadic medulloblastoma and 
are said to be the reason for the constitutive activation of this signalling pathway (Johnson 
et al. 1996, Hahn et al. 1999, Northcott et al. 2009, Adamson et al. 2010, Northcott et al. 
2011). This spectrum of mutations together with the fact that a subgroup of 
medulloblastoma show a pathological activation of the SHH pathway indicates that a 
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dysregulation of this pathway plays an important role in the development of 
medulloblastoma. Furthermore, dysregulation of the Shh pathway plays a role in the 
induction of tumors occurring in different human tissues, such as Basal cell carcinoma 
(Athar et al. 2014) or Pancreatic ductal carcinoma (Lauth and Toftgard 2011). Molecules 
targeting different components of the Sonic hedgehog pathway, such as the Smoothened 
inhibitor Vismodegib, have already been subject of clinical trials aiming at the 
consolidation of novel therapeutic approaches against Shh-driven neoplastic pathologies 
(Sekulic et al. 2012). 
In addition to the molecular distinctions among MB subtypes, a number of signalling 
pathways are found to be activated across multiple subtypes of the disease. For example, 
the phosphatidylinositol 3-kinase (PI3K) pathway is activated in WNT (Robinson et al. 
2012), SHH (Northcott et al. 2012), and Group 3 MB (Pei et al. 2012), and genes 
responsible for histone methylation and chromatin remodelling (MLL2, MLL3, KDM6A, 
EZH2, ZMYM3) are deregulated in both Group 3 and Group 4 MBs (Pugh et al. 2012, 
Robinson et al. 2012). 
 
1.3.3.3 Interaction of Wnt and Shh signalling 
 
It has been reported that sonic hedgehog (SHH) signalling and Wnt signalling interact in 
tumors. For example, in colorectal cancer, overexpression of Gli1 (a downstream 
component of the SHH signalling pathway) inhibits Wnt signalling and colorectal cancer 
cell proliferation, even in cells possessing the stabilizing mutation of ß-catenin (Akiyoshi 
et al. 2006). In neural progenitors, Wnt signalling and SHH signalling coordinately 
regulate cell cycle progression, with SHH signalling activation required upstream 
(Alvarez-Medina et al. 2009). The Wnt/beta-catenin and the Hedgehog (Hh) pathway 
interact in various cell types while eliciting opposing or synergistic cellular effects. Both 
pathways are known as exclusive drivers of two distinct molecular subtypes of MB. In 
sonic hedgehog (Shh)-driven MB, activation of Wnt signalling has been shown to suppress 
tumor growth by either beta-catenin-dependent or -independent inhibition of Shh 
signalling (Anne et al. 2013, Peng et al. 2013, Pöschl et al. 2014). However, neither 
mechanistic insight into β-catenin-mediated inhibition of the Hh pathway, nor the 
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therapeutic potential of Wnt/β-catenin-activating drugs has been examined specifically 
in MB. Recently, Zinke et al. propose that beta-catenin stabilization increases its physical 
interaction with Gli1, leading to Gli1 degradation and inhibition of Hh signalling, thereby 
promoting tumor cell senescence and suppression of “tumor take” in mice (Zinke et al. 
2015). 
 
1.3.4 Mouse models  
 
In order to better understand and analyse genetic, molecular and cytological influences 
on the development of medulloblastoma, different mouse models are available, which are 
based on different mutations and genetic systems depending on the group of tumor. 
It is currently thought that tumor cells of the SHH type of medulloblastoma originate from 
the granule cell progenitors in the external granular layer. Indeed the vast majority of 
these cells express markers of the proliferating external granular layer, the most common 
of which is ATOH1 (MATH1). More recently, it was demonstrated that Atoh1 protein 
expression was crucial for the progression of this type of tumor (Flora et al. 2009) because 
this transcription factor potently regulates the proliferation of granule cell progenitors in 
mice (Klisch et al. 2011). This likely occurs by Atoh1 maintaining the sensitivity of 
progenitor cells to Shh signalling through transcriptional activation of the Gli2 gene. 
Moreover, several groups have generated mouse models for key elements of the SHH 
subgroup of human medulloblastomas. 
One of the first and most used genetically engineered mouse model (GEMM) for the Shh-
associated medulloblastoma is based on a conventional knockout of the Shh-repressor 
Patched (Ptch1). This first Ptch+/- mouse model was generated by homologous 
recombination in embryonic stem cells, in which part of Ptch exon 1 (including the 
putative start codon) and all of exon 2 were replaced with lacZ and a neomycin resistance 
gene (Goodrich et al. 1997). Homozygous deletion of Ptch1 (Ptch1-/-) in the mouse is 
embryonic lethal, but 20% of mice with a heterozygous Ptch1-knockout (Ptch1+/-) develop 
tumors in the cerebellum, which are molecularly very similar to human medulloblastoma 
(Goodrich et al. 1997, Hahn et al. 2000). Simultaneous loss of the tumor suppressor p53 
(Tp53-/-) leads to a tumor incidence of 100% and illustrates cooperative functional 
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mechanisms in tumor development (Wetmore et al. 2001). Similar effects were observed 
in knockouts of cell cycle regulators p18-Ink4c and p27-Kip in Ptch1+/- mice (Uziel et al. 
2005, Uziel et al. 2006, Ayrault et al. 2009). A disadvantage of the Ptch1 mouse model for 
development of medulloblastoma is the simultaneous appearance of soft tissue tumors 
(Wetmore et al. 2001, Lee et al. 2006). 
Activation of other components of the Shh pathway can also lead to the development of 
medulloblastoma. It has been shown via RCAS/TVA-systems that Nestin-positive 
precursor cells can develop medulloblastoma in 10-15% of cases after transduction with 
RCAS-based retrovirus which are coding for Shh (Rao et al. 2003, Broderick et al. 2004, 
Browd et al. 2006, Binning et al. 2008). Here RCAS (replication competent ASLV long 
terminal repeat with Splice acceptor)-based retrovirus can just transduce cells which 
express TVA (avian retrovirus receptor) under the Nestin promoter and therefore enables 
a cell-specific activation of the Shh pathway. 
A very robust mouse model for Shh-associated medulloblastoma was generated by 
expression of a constitutive activated form of the Smoothened gene (SmoA1) under the 
granule cell precursor specific promoter ND2 (Hallahan et al. 2004, Hatton et al. 2008). 
Almost 100% of the animals developed a tumor which also metastasizes in the 
leptomeningeal region, a characteristic of many human tumors. Analogous to RCAS-based 
mouse model mentioned above, tumor development outside the CNS can be avoided. 
At the moment the most popular mouse models for Shh-associated medulloblastoma are 
based on conditional systems like the Cre/loxP-recombination system, which allows a 
tissue- and cell type-specific recombination and therefore manipulation. Independent of 
the temporal activity of the promoter, mutations are activated cell type specifically by 
injection of an oestrogen analogue (Tamoxifen) (Leone et al. 2003, Erdmann et al. 2007, 
Arnold et al. 2011). The cell type specific activation of the Shh pathway with special Cre 
mouse strains (Math1-cre for granule cell precursors, hGFAP-cre for neural precursors) 
increased the tumor penetrance up to 100% without a simultaneous knockout of further 
tumor suppressors. Therefore the Shh-repressor Ptch1 is promoter specifically deleted or 
a constitutive activated form of Smoothened gene (SmoM2-YFP) is transcribed, what is 
leading, in both cases, to an activation of Shh signalling and a subsequent development of 
medulloblastoma (Mao et al. 2006, Schüller et al. 2008, Yang et al. 2008). 
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While all mouse models mentioned above imitate human SHH-associated 
medulloblastoma, the number of mouse models for WNT-, Group 3- and Group 4- 
subgroups are very limited. Recently a mouse model for human WNT-associated 
medulloblastoma was described (Gibson et al. 2010). Here tumors were generated 
through activation of the Wnt pathway in cell populations of the dorsal brainstem with a 
simultaneous knockout of the tumor suppressor p53, which are molecularly similar to 
human WNT-medulloblastoma. For the first time it was shown that the cell of origin of 
WNT medulloblastoma lies not necessarily in the cerebellum. Interestingly, the 
comparison of the model for Shh- and Wnt-associated medulloblastoma showed that they 
really develop from different cell of origins (Gibson et al. 2010). Shh-medulloblastoma 
develop from the upper part of the rhombic lip, or in the auditory part of the lower 
rhombic lip, whereas Wnt-tumors develop in the precerebellar part of the lower rhombic 
lip (Grammel et al. 2012). 
Limited data from two different mouse models for Group 3 medulloblastoma were 
generated through expression of c-MYC in cerebellar precursor cells and an additional 
knockout of p53 (Kawauchi et al. 2012, Pei et al. 2012). The fact that Group 3 
medulloblastoma are the most aggressive subgroup with the least survival rate, illustrates 
the need to generate appropriate mouse models for this subgroup with regard to 
preclinical studies. 
For Group 4 medulloblastoma no reliable mouse model exists at the moment. 
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1.4 Aim of the study 
 
My focus of research is the development, diagnosis and therapy of medulloblastoma, the 
most malignant brain tumor in children. Medulloblastoma possibly develop very early, 
already during embryonic development. 
Recent clinical trials for SHH-MB using SMO antagonists showed highly variable clinical 
responses including a large proportion of striking durable responders, but also a lot of 
non-responders. Recent sequencing data from an unprecedented series of SHH-MB 
(n=133) showed that about half of pediatric SHH-MB are predicted to be primarily 
resistant to these drugs because of mutations downstream of SMO. Moreover, it is known 
that some initially responsive tumors may also rapidly acquire secondary resistance to 
treatment, whereas other patients keep in remission for several years on a single targeted 
drug.  
One part of this study deals with the localization of SHH MBs. Since we know that the 
localization of human SHH MBs differs depending on the age of the patient, we wanted to 
analyse this statement more precisely at different ages in an already existing mouse 
model for SHH MBs. The aim is to determine if such murine SHH MBs develop at special 
time points and/or at defined localizations. 
Another point of this study intends to investigate the diverging role of synchronistic Wnt 
and Shh activation and deals with the question whether the physiological roles of Wnt/ß-
catenin signalling can be utilized to treat Shh-medulloblastomas. In vitro experiments 
were carried out, aiming at the possible use of Lithium, a Wnt activator, in the therapy of 
Shh-driven medulloblastoma. 
 
Finally, we aimed at a better understanding of the mechanisms in MB of primary and 
secondary resistance to various drugs targeting the hedgehog pathway. To this end, we 
generated, characterized and used genetically engineered mouse models (GEMMs) of 
SHH-MB. We aimed to further expand our pre-existing repertoire of murine SHH-
activated MB models in order to have a spectrum of tumors that are driven by mutations 
at different levels of the Hh pathway, such as in PTCH1, SMO or MYCN, and with different 
combinations of other mutations in additional pathway that may co-operate with Hh 
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signalling (e.g. TP53 or PIK3CA). We treated some of these models with drugs targeting 
the Hh pathway. We tested LDE225, a SMO inhibitor that already have entered clinical 
trials. Mice were monitored for treatment response, development of secondary drug 
resistance, and overall survival. Tumors will be molecularly characterized by sequencing 
and gene expression profiling, and data will be compared to untreated tumors. 
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2 Materials and methods 
2.1 Experimental animal studies 
2.1.1 Mouse strains 
 
In this work wild type mice of the strains C57/Bl6 and FVB and a number of transgenic 
mouse models were used. SmoM2-YFPFl/Fl (Mao et al. 2006), aiTdTomato (Madisen et al. 
(2010), Ptch1+/- (Goodrich et al. 1997, Oliver et al. 2005), Ctnnb1(ex3)Fl/Fl (Harada et al., 
1999; Pöschl et al., 2013), GSK3ßFl/Fl (Jaworski et al., 2011), Math1-GFP (Lumpkin et al., 
2003), Ptch1Fl/Fl (Uhmann et al., 2007), Pik3caH1047R (Adams et al., 2011), P53 (Marino et 
al., 2000), lsl-Mycn (Althoff et al., 2015). 
In addition, the driver lines Math1-cre (Matei et al., 2005; Schüller et al., 2007) and Math1-
creERT2 (Machold and Fishell, 2005) were used. 
Mice were hold in a SPF-animal facility (specific-pathogen-free) in individually ventilated 
cages (IVC) with a constant light-dark rhythm of 12/12 hours. Food and water were given 
ad libitum. For preparation of the brain adult mice were sacrificed by cervical dislocation. 
Animals under 10 days were sacrificed by decapitation. For removal of the brain the 
cranial bone was opened and removed until the surface was laid open from the olfactory 
bulb anterior till the hindbrain. The brain was lifted out of the skull by cutting through the 
optical nerve at the optic chiasm and the brain nerves under the brain stem. 
All experimental procedures were approved by the Government of Upper Bavaria, 
Germany (Reference number 55.2-1-54-2532-10-14 and 55.2-1-55-2532-56-15). 
 
2.1.1.1 Conditional knockout mice 
 
By mating a cre-driverline with one or more transgenic mouse strains, conditional Cre-
loxP-systems are created. This means that the cre-recombinase is expressed under the 
promoter (here Math1-cre), which is able to initiate recombination between so called lox-
P-Sites on the DNA and therefore delete everything located between the lox-P-Sites. 
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2.1.1.2 Inducible knockout mice 
 
By induction with the oestrogen analogue tamoxifen mutations can be created under the 
Math1-promoter (Math1-creERT2) at defined time points. Mice with this genetic 
background express the transgene after successful recombination promoter-specific. 
Under the Math1-promoter a transgenic oestrogen receptor is expressed which allows the 
translocation of the cre-recombinase from the cytoplasm into the nucleus only after 
binding of tamoxifen. Here the enzyme can remove the STOP-sequences in front of the 
genes by recombination. Thus the expression of the transgene depends on the activity of 
the Math1-promoter and the time point of the tamoxifen induction.  
 
2.1.2 Tamoxifen induction and BrdU pulse 
 
The tamoxifen-inducible mouse model Math1-creERT2 makes it possible to activate the cre 
recombinase specifically during the postnatal development in Math1-positive granule cell 
precursors of the cerebellum. The fusion protein of the cre recombinase and a mutated 
form of the human oestrogen receptor is expressed under the Math1-promoter in this 
mouse line, but it is retained in the cytoplasm of the cell. Only after tamoxifen induction it 
reaches the nucleus and became active (Feil et al., 1997; Helms et al., 2000; Machold and 
Fishell, 2005). Mice with this inducible cre system were induced by tamoxifen (Sigma 
Aldrich) either at postnatal day 3 or 5 or pregnant dams were induced at embryonic day 
14.5. Therefore 1 mg tamoxifen (in cornoil) is administered intraperitoneal (i.p.). 
For analysis of the proliferation rate of cerebellar granule cells in vivo in different mouse 
models a bromodesoxyuridine (BrdU)–pulse was performed and mice were sacrificed 2 
hours later. Therefore the animals were administered 25 µg/g body weight 
intraperitoneal. BrdU is integrated in the DNA as a chemical analogue of the nucleoside 
thymidine and can be verified immunohistochemically afterwards. After a 2 hour BrdU-
pulse, cells which were in the S–phase of the cell cycle can be verified. 
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2.1.3 Treatment of mice with LDE225 in vivo 
 
Mice (Math1creERT2::lsl-SmoM2Fl/+, Math1-creERT2::lsl-SmoM2Fl/+ lsl-Pik3caFl/+ and 
Math1creERT2::Ptch1Fl/Fl) were treated with the hedgehog inhibitor (via smoothened 
antagonism) LDE225, also known as Sonidegib/Erismodegib (sponsored by Novartis; 
marketed as Odomzo). Treatment start was at postnatal day 30 or 20. Each mouse was 
treated 5 times per week for three weeks long with a dose of 30 mg/kg/day (i.p.). LDE225 
was dissolved in DMSO and this solution was then mixed with 40% polyethylene glycol 
(PEG). Each injection was 100 µl i.p. (5 µl LDE225 dissolved in DMSO + 95 µl 40% PEG 
were mixed directly before usage). The vehicle group was treated with 5 µl DMSO + 95 µl 
40% PEG. 
 
2.1.4 DNA extraction and genotyping 
 
DNA for genotype verification through PCR and electrophoresis was extracted from 
mouse tail (early postnatal stages) or ear biopsies (older than 3 weeks). Each biopsy was 
first treated with 500 µl Laird´s lyses buffer (200 mM NaCl, 100 mM Tris buffer (pH 8.5), 
5 mM EDTA, 0.2% SDS) and 10 µl Proteinase K (10 mg/ml) on a thermo-shaker at 56°C 
for at least 2 hours. Samples were than centrifuged (14.000 U) at room temperature for 5 
minutes. The supernatant containing the DNA was then extracted into a new tube and 500 
µl Isopropanol were added. After mixing, the precipitated DNA became visible. 
Centrifugation at room temperature with 14.000 U for 5 minutes was repeated. Finally, 
the remaining Isopropanol was discarded and the DNA pellet was resuspended in TE-
Buffer (20 nM Tris-HCl pH 8.3, 1 mM EDTA in ddH2O) and then stored at 4°C. 
The genomic DNA (gDNA) is the starting material for genotyping. Therefore genotype-
specific regions of the genome were amplified by polymerase chain reaction (PCR). 
Primers are listed in Table 1 according to primary descriptions of the mouse strains in 
original publications. 
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Primer name  Sequence 5’ – 3’ Product length 
Cre-Fw TCCGGGCTGCCACGACCAA  
Cre-Rv GGCGCGGCAACACCATTTT 448 bp 
SmoM2-YFP Mut-Fw GAACGGCATCAAGGTGAA  
SmoM2-YFP Mut-Rv CGATGGGGGTGTTCTGCT 109 bp 
SmoM2-YFP WT-Fw GGAGCGGGAGAAATGGATATG  
SmoM2-YFP WT-Rv CGTGATCTGCAACTCCAGTC 410 bp 
tdTomato Mu-Fw GGCATTAAAGCAGCGTATCC  
tdTomato Mu-Rv CTGTTCCTGTACGGCATGG 196 bp 
tdTomato WT-Fw AAGGGAGCTGCAGTGGAGTA  
tdTomato WT-Rv CCGAAAATCTGTGGGAAGTC 297 bp 
Ctnnb1(ex3)Fl/Fl Fw CGTGGACAATGGCTACTCAA 330 bp (wildtype), 
Ctnnb1(ex3)Fl/Fl Rv TGTCCAACTCCATCAGGTCA 500 bp (mutant) 
GSK3ß Fw TCTGGGCTATAGCTATCTAG 302 bp (wildtype), 
GSK3ß Rv CGAAAGTGATTGGAAATGGA 488 bp (mutant) 
Math1 GFP Mut Rv AGGGTCAGCTTGCCGTAGGT  
Math1 GFP Fw GCGATGATGGCACAGAAGG 200 bp (wildtype), 
Math1 GFP WT Rv GAAGGGCATTTGGTTGTCTCAG 314 bp (mutant) 
MYCN MU Fw ACCACAAGGCCCTCAGTACC  
MYCN MU Rev TGGGACGCACAGTGATGG 168 bp 
MYCN WT Fw CTCTTCCCTCGTGATCTGCAACTCC  
MYCN WT Rev CATGTCTTTAATCTACCTCGATGG 299 bp 
P53 Fw CACAAAAAACAGGTTAAACCCAGC 288 bp (wildtype), 
P53 Rv GCACCTTTGATCCCAGCACATA 370 bp (mutant) 
Ptch1 Fl Fw TTCATTGAACCTTGGGGAAC 216 bp (wildtype), 
Ptch1 Fl Rv AGTGCGTGACACAGATCAGC 269 bp (mutant) 
Ptch1 ko Fw TTCACTGGCCGTCGTTTTACAACGTCGTGA  
Ptch1 ko Rv ATGTGAGCGAGTAACAACCCGTCGGATTCT 364 bp 
Pik3ca 1 AAAGTCGCTCTGAGTTGTTAT 600 bp (wildtype), 
Pik3ca 2 GCGAAGAGTTTGTCCTCAACC 310 (mutant), 
Pik3ca 3 GGAGCGGGAGAAATGGATATG 410 bp (Pi3k) 
Table 1 List of primers for genotyping. 
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Standard conditions the genotyping PCR are as follows (Table 2): 
 
step temperature [°C] time [s]  
pre-incubation 95 120  
denaturation 95 30  
primer hybridisation 60 30  35 cycles 
elongation 72 60  
stop 4 ∞  
Table 2 PCR conditions for genotyping. 
 
Analysis of the amplified DNA-fragments was carried out by 1% agarose gels and the 
Syngene gel documentation system (Synoptics Limited). 
 
2.1.5 Primary cell culture 
2.1.5.1 Cerebellar granule neuron precursor cells 
 
Well plates were coated with 1x poly-L-ornithine (PLO) (Sigma) from a 100x stock (10 
mg/ml). Dilution was carried out in H2O and 0.2 µM sterile filters were used in order to 
preserve poly-L-ornithine. The plates were than incubated at 37°C during mouse 
preparation allowing poly-ornithine to polymerise. Mouse cerebella were dissected at 
postnatal day 5-7 and put on ice in 15 ml Hanks buffered saline solution (Gibco, pH 7.4 
Glucose 6 mg/L). After centrifugation at 4°C for 5 minutes with 800 rpm, HBSS was 
discarded. 1 ml of 1x Trypsin/EDTA/DNAse (100 µg DNAse/ml, both Trypsin/EDTA and 
DNAse were from Sigma) was added and the cerebella were left 10 minutes in water bath 
for incubation. Trypsin was then inactivated with 2 ml of DMEM-F12 +10% fetal bovine 
serum (fetal bovine serum was inactivated at 56°C for 30 minutes prior to usage). Next, 
the cerebella were centrifuged at 4°C with 1500 g for 5 minutes. The fetal bovine serum 
medium was aspirated and substituted with 5 ml HBSS solution. The pellets were 
dissolved by pipetting gently and a new centrifugation step (as above) was conducted. 
After discarding supernatant HBSS, the pellets were resuspended in 1 ml HBSS and spun 
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as above. The HBSS remnant was extracted and the cells were put into suspension with 
culture medium with supplements (DMEM-F12, 1% N2 Supplement, 1% 
Penicillin/Streptomycin, 0.25 mM KCl with 10% FCS. All reagents were from Invitrogen). 
The poly-L-ornithine solution was removed and each well was washed with PBS once. 
Granule neuron precursors were then plated in serum-free culture medium with 
supplements at a concentration of 1 million cells/well and grown at 37°C and 5% CO2. 
After 6-12 hours the medium was removed and culture medium with Shh-protein (3 
µg/ml) was added. Due to culturing with this medium for at least 24 hours, all cells except 
cerebellar granule cells leave the cell cycle and a homogeneous proliferating granule cell 
population remained. For transduction of granule cells with IRES-GFP and Cre-IRES-GFP 
virus, the medium was removed and the virus supernatant (see 2.5.3 production of 
retroviral particles) was added to the cells for 4 hours. Due to the fact that retrovirus just 
transduce proliferating cells and culturing in selective Shh-medium, it was prevented that 
other cell types than granule cells could be transduced with the virus. After virus 
transduction cells were again cultured in culture medium with Shh-protein for 24 hours. 
For analysis of the proliferation rate bromodesoxyuridin (BrdU, 25 µg/ml) was added to 
the medium, and cells were fixed after two hours with 4% paraformaldehyde. 
 
2.1.5.2 Tumor cells 
 
Tumor cell culture was performed as described for culturing GNPs with the following 
exceptions: tumor cells were maintained in Neurobasal medium containing B27 
supplement, human FGF (20 ng/ml), mouse EGF (20 ng/ml), glutamin (2 mM) and 
Pen/Strep (100 µg/ml). Here no Shh-protein was added to the medium because cultured 
tumor cells from our mouse strains for Shh-associated medulloblastoma have a 
constitutive activated Shh signalling pathway anyway. 
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2.2 Histology and immunohistochemistry 
 
For all histological methods, brains were dissected, fixed overnight in 4% 
paraformaldehyde, embedded in paraffin, and sectioned at 5 µm according to standard 
protocols. Paraffin sections were deparaffinised with xylene and rehydrated in a graded 
alcohol series. In general morphology was analysed with Hematoxylin and eosin (H&E) 
stains. H&E stains were performed according to standard protocols. 
All histological photomicrographs were taken digitally using an Olympus BX50 
microscope in combination with the ColorView (Soft Imaging System). 
 
For immunohistochemistry, paraffin sections were subjected to heat antigen retrieval at 
100°C for 20 min in 10 mM sodium citrate buffer for all antibodies. For inactivation of the 
endogene peroxidase all slides were incubated in 5% H2O2 in methanol. Then the slides 
were washed in PBS, blocked for 30 min in I-Block reagent (Invitrogen) and incubated 
over night with the primary antibody at 4°C. 
All primary antibodies for immunohistochemistry and immunocytochemistry are listed 
in Table 3. 
 
antibody species Catalog # vendor/provider 
BrdU mouse 10198 Bioscience Products 
BrdU rat ab6326 Abcam 
GFP rabbit sc-9334 Santa Cruz 
Ki67 rabbit ab16667 Abcam 
RFP rabbit AA234 Antibodies online 
Sox2 mouse ab79352 Abcam 
Sox2 rabbit ab97959 Abcam 
Table 3 Primary antibodies for immunohistochemistry and immunocytochemistry. 
 
Staining was performed using the HRP/DAB staining system (DAKO) according to the 
manufacturer’s specifications. For immunofluorescence staining slides were washed with 
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PBS after incubation with the first antibody and incubated with a species-specific, 
fluorophore-coupled secondary antibody (Alexa 488 and Alexa 546, Invitrogen). Staining 
of the nuclei was done by 4’,6-Diamidin-2-phenylindol (DAPI; Roth). For fluorescent 
staining of cell culture the same protocol was used as for immunofluorescence staining, 
but without deparaffination and rehydration. Pictures of fluorescent staining were taken 
with an Olympus IX50 microscope. 
 
2.2.1 BrdU staining 
 
The immunohistochemical detection of the incorporation of the base analogue BrdU in 
the DNA instead of the physiological nucleoside thymidine requires another pre-
treatment before the incubation with the first antibody. To permit the access for the BrdU-
specific antibody to the antigene, DNA has to be denaturated with 2N HCl for 10 min and 
then the acid has to be neutralized with 0.1 M sodium borat buffer (pH 8.5), not to impair 
the structure of the primary antibody. 
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2.3 Molecular biological methods 
2.3.1 RNA extraction, cDNA synthesis and qRT-PCR 
 
Both cultured cells and tissue samples were first put into Eppendorf tubes and 
homogenised with 750 µl TRlzol® (Invitrogen) reagent using a pipette, before proceeding 
with RNA extraction. The homogenised samples were let sit at room temperature for 
about 5 min. 150 µl of chloroform were added to each tube. After mixing for 15 sec, the 
samples were incubated at room temperature for 3 min. A centrifugation step with 14.000 
rpm at 4°C was conducted for 15 min, after which the supernatant, RNA-containing top 
layer was extracted into a new Eppendorf tube. The RNA was then precipitated with cold 
(4°C) isopropanol and incubated at room temperature for 10 min. A centrifugation step 
was repeated as described above. Eventually, the RNA pellet became visible at the bottom 
of the tubes. The supernatant liquid was discarded and the RNA pellet was washed with 
75% ethanol. After brief shaking, each sample was centrifuged for 5 min at 4°C with 7500 
rpm. Ethanol was discarded, and the RNA pellets were resuspended in 24 µl DEPC water 
each. The RNA concentration was determined through Nanodrop 3300 technology 
(Thermo Fischer Scientific). cDNA synthesis for RT-PCR was performed using 
SuperScript® III First-Strand Synthesis Supermix (Invitrogen). Each component was 
mixed and centrifuged before use. For each RNA sample the reaction mix consisted of the 
following reagents: 6 µl of RNA (in DEPC water, up to 5 µg RNA), 0.5 µl oligo(dT)20 primer 
(50 µM), 0.5 µl of random hexamers (50 ng/µl), 1 µl annealing buffer, RNAse/DNAse-free 
water to bring the total volume up to 8 µl. After heating at 65°C for 5 min in a thermo-
cycler, the tubes were put on ice for 1 min. Leaving the tubes on ice, the following solutions 
were added to each reaction mix: 10 µl First-Strand Reaction Mix (2x), 2 µl SuperScript® 
III/ RNaseOUTTM Enzyme Mix. The tubes were than mixed by vortexing and centrifuged 
briefly. The samples were incubated in a thermo-cycler for 5 min at 25°C, 50 min at 50°C 
and finally at 85°C for 5 min. Finally, the cDNA was cooled down on ice and stored at -
20°C.  
Quantitative real-time PCR (qRT-PCR) was carried out using the LightCycler® 480 (Roche) 
technology and the LightCycler® 480 SYBR Green I Master Mix (Roche). SYBR Green is a 
fluorescent cDNA-intercalating dye, which is detected and quantified after each 
elongation step, therefore allowing cDNA quantification in real time. Each reaction mix 
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contained the following agents: FastStart Taq DNA Polymerase and SYBR Green dye 
(Roche), 3 µl of cDNA, 1 µl forward primer and 1 µl reverse primer (primer stocks 
concentration: 100 pmol/µl). Before usage, each primer was diluted 1:10 in DNAse free 
water. A RT-PCR program was conducted, which included the following steps: heat shock 
at 95°C for 5 min, then 45-cycles containing the following steps: denaturation at 95°C for 
10 seconds, annealing at 57-62°C for 10 seconds, elongation at 72°C for 15 seconds. 
Relative quantification was achieved by comparing cDNA levels between target genes and 
housekeeper genes (β2-Microglobulin (β2M)). Besides this, a calibrating sample was used 
for each LightCycler® run within a single experiment, in order to compensate variations 
of the reaction mix composition. All samples were analysed in triplicates. The following 
formula was applied for relative quantification: 
NR=ET CpT(C) - CpT(S) x ER CpR(S) - CpR(C) 
NR=normalized ratio, E=primer efficiency, T=target gene, C=calibrating sample, 
R=housekeeper gene, S=sample, Cp=crossing point (number of cycles after which the 
SYBR Green detection threshold is reached). 
All primers were designed using the Primer3 software and ordered from Eurofins 
Genomics. Amplicon melting curves were analysed to determine the presence of a single 
PCR product, primer quality and primer efficiencies were calculated based on standard 
curves. Table 4 shows primer pairs sequences and efficiencies. 
 
gene sequence efficiency annealing 
β2M Fw CCTGGTCTTTCTGGTGCTTG 2.23 60°C 
β2M Rv TATGTTCGGCTTCCCATTCT   
Axin2 Fw GCTGGTTGTCACCTACTTTTTCT 1.81 62°C 
Axin2 Rv ATTCGTCACTCGCCTTCTTG   
Gli1 Fw CGCCCCGACGGAGGTCTCTT 1.964 60°C 
Gli2 Rv GCTGGCCGTCCCAACTGCTT   
Table 4 Primers for qRT-PCR. 
 
Standard conditions for RT-PCR are summarized in Table 5. 
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step detection mode temperature [°C] time [s]  
preincubation  95 300  
denaturation  95 10  
primer hypridisation single 60 10 45 cycles 
elongation  72 20  
melting curve 
analysis 
continuous 40-95 300  
stop  4 ∞  
Table 5 Conditions for qRT-PCR. 
 
2.3.2 Production of retroviral particles 
 
Retroviral particle for transduction of primary mouse cells were produced by transfection 
of human HEK293T cells (American Type Culture Collection, ATCC). The work with 
eukaryotic cells was done with sterile vessels and solutions in a sterile environment 
(HERAsafe, Thermo). HEK293T cells were cultured in incubators at 37°C and 5% CO2. For 
production of retroviral particles, HEK239T cells were transfected in a triple-transfection 
with two helper plasmids (pCMV-VsVg and pCMV-gag-pol) and each with a retroviral 
construct with only IRES (internal ribosome entry-site)-GFP or with a Cre (Cre-
recombinase)-IRES-GFP sequence using the transfection reagent X-tremeGENE HP 
(Roche). The medium was replaced after 24 hours with normal culture medium (DMEM 
medium, 10% foetal calf serum, 1% Glutamax). The supernatant of the retroviral medium 
was taken up to 4 days after transfection and cleaned with 0.45 mm filters and stored at -
80°C. 
 
2.3.3 Colorimetric MTT-assay 
 
The colorimetric MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)- 
assay is a spectrophotometer-based method used to quantify cell growth or cytotoxicity 
rates (Finlay et al. 1986, Vistica et al. 1991). The tetrazolium salt MTT is chemically 
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reduced by ribosomes in metabolic active cells, forming formazan crystals. The resulting 
change of solution colour is than quantified through spectrophotometric absorbance 
measure. For this work, the Cell Proliferation Kit I (MTT) from Roche was used. Cells were 
first seeded in 100 µl in 96-well plates at a concentration of 2x104/well and incubated 
(37°C) in neurobasal culture medium with supplements (see also 2.1.5 Primary cell 
culture) for 16 hours. Spectrophotometric absorbance was determined using the 
FLUOstar Optima (BMG labtech) system. For lithium chloride treatment, start point of 
therapy was defined by adding 10 µl of the MTT reagent to at least three wells and adding 
the Solubilisation solution (100 µl) after 4 hours, in order to quantify cell viability at time 
point 0 (T0). After 24 hours (T1), 10 µl of the MTT reagent were put into the remaining 
wells (at least in triplicates) for 4 hours, after which, the Solubilisation solution (100 µl) 
was added into each well. One well was left without MTT and served as a blank sample. 
The plates were let sit in the incubator overnight and the optical density (OD) at T0 and T1 
was determined as follows: ODT – ODblank. Cell viability after 24 hours (T1) was calculated 
using the following formula: ODT0/ODT1= 100%/x.  
 
2.3.4 Cell Lines 
 
HEK 293T cells arise from human embryonic kidney cells, which were originally 
transformed with Adenovirus 5 DNA (Graham et al. 1977). UW473 are a human 
medulloblastoma cell line obtained from a pediatric tumor sample (Bobola et al. 2005, 
Castro-Gamero et al. 2013). GL261 cells derive from the GL261 mouse glioma model. This 
murine model was first developed through application of a chemical carcinogen into the 
brain of C57BL/6 mice and then perpetuated by means of syngeneic transplantation 
(Maes et al. 2011). All three cell lines proliferated as adherent monolayers and were 
cultured in DMEM medium with 10% fetal calf serum, 1% Glutamax (Invitrogen), 1% 
Penicillin/Streptomycin (Invitrogen) and 1% HEPES buffer (Sigma). 
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2.3.5 Lithium chloride treatment in vitro 
 
In our in vitro setting, lithium chloride was balanced with NaCl in order to achieve equal 
salt concentrations of 25 mM in every well.  
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2.4 Statistical analyses 
 
The Prism5.02 software (GraphPad) was used for statistical analysis. Survival data were 
obtained through Kaplan-Meier curves and the Log-rank test served as significance test. 
P-values < 0.05 were considered as significant. When comparing two groups with 
assumed Gaussian distribution and equal variances, the unpaired t-test was conducted. In 
case of not equal variances or an expected non-Gaussian distribution, the non-parametric 
Mann-Whitney test was used. For testing distributions for their significance between two 
groups, the χ² test was used. For RT-PCR and MTT-assays a number of at least three 
samples was analysed for each experimental condition or mouse genotype. 
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3 Results 
3.1 Establishment and characterisation of mouse models for SHH 
medulloblastoma 
 
 
 
Figure 5 Hh signalling pathway. Binding of SHH to PTCH1 releases PTCH1-mediated inhibition of SMO, 
resulting in activation of GLI transcription factors and expression of target genes. PI3K/AKT/mTOR 
enhance GLI1 activity. BRD4 (bromodomain 4) binds to the MYCN promoter. The pharmacological inhibitor 
LDE225 is indicated in red. 
 
Components of the canonical Hh signalling pathway are Hh ligands such as sonic 
hedgehog (SHH), the transmembrane protein PTCH1 that acts as a receptor for Hh ligands, 
SMO, a transmembrane protein and signalling partner of PTCH1, and the family of GLI 
transcription factors (Zibat et al. 2010). In the absence of SHH, PTCH1 inhibits SMO. 
Binding of SHH to PTCH1 suspends this PTCH1-mediated inhibition of SMO, which in turn 
activates GLI transcription factors, resulting in the expression of target genes including 
GLI1. GLI1 activity is increased upon its phosphorylation by e.g. PI3K/AKT/mTOR (Figure 
5). 
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Recent clinical trials for SHH-MB using SMO antagonists showed highly variable clinical 
responses including a large proportion of striking durable responders, but also a lot of 
non-responders. Recent sequencing data (Kool et al. 2014) from an unprecedented series 
of SHH-MB (n = 133) showed that about half of pediatric SHH-MB are predicted to be 
primarily resistant to these drugs because of mutations downstream of SMO. Moreover, it 
is known that some initially responsive tumors may also rapidly acquire secondary 
resistance to treatment, whereas other patients keep in remission for several years on a 
single targeted drug. 
In order to establish novel therapies that are based on the individual genetic and 
molecular profile of a patient’s SHH-MB, we wanted to expand our battery of genetically 
engineered mouse models (GEMMs) based on mutations at different levels of the Hh 
signalling cascade. Apart from using already established mice with mutations in PTCH1 
and SMO we wanted to generate novel additional models that faithfully model human 
SHH-MB with amplifications of e.g. MYCN. All these models are also be modified with 
respect to additional mutations in TP53 or PIK3CA, strictly representing the findings in 
human SHH-MB. 
All mice were exposed to tamoxifen and monitored for symptoms of tumor growth, head 
growth, drinking behaviour, movements, weight and neurological symptoms, such as 
ataxia, paralysis or seizures. Animals that developed symptoms were sacrificed and one 
half of the cerebella were subjected to histological analysis to confirm the presence of 
tumors, and of the other half of the cerebella tumor tissue was harvested for further 
analysis. 
 
3.1.1 Mouse model with SMO mutation 
 
Here we used the Cre-LoxP-recombination system to ensure the constitutive activation of 
the Shh pathway. Therefore the enzyme cre-recombinase is able to cut out so called floxed 
sequences in the genome of mice, which are framed by loxP-sequences in vivo. For the 
constitutive activation of the Shh pathway a floxed mouse strain was available which 
allows a cre-mediated, conditional expression of a mutated Smo-allele (SmoM2-YFP) 
together with YFP-sequences (Mao et al. 2006). Mice with a mutation in the Smoothened 
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receptor (SmoM2) under the tamoxifen-inducible Math1-creERT2-promoter (MATH1 is a 
marker for cerebellar granule precursor cells) were generated. Through administration 
of tamoxifen at postnatal day 3 (P3), the Shh pathway can be constitutively activated in 
cerebellar granule cell precursors which leads to the development of SHH-associated 
medulloblastoma and often to the development of a hydrocephalus. The tumor incidence 
is 100%. Here the heterozygosity (one activated SmoM2 allele) is sufficient for tumor 
development (Math1-creERT2::lsl-SmoM2Fl/+). The median survival of these mice is 65 days 
(Figure 6 i). Tumor mice developed symptoms like abnormal head growth, ataxia and loss 
of weight. All tumors display classic histology (Supplementary Figure 25). 
 
3.1.2 Mouse model with SMO and PIK3CA mutations 
 
The phosphoinositide 3-kinase (PI3K) signalling pathway is one of the most frequently 
mutated pathways in cancer and plays an important role for proliferation in human 
tumors. The Pik3caH1047R model was first described by (Adams et al. 2011). H1047R 
mutations in the kinase domain account for approximately 40% of breast cancer PIK3CA 
mutant alleles (Saal et al. 2005). Although PIK3CA mutations are common in adult cancers 
(Samuels et al. 2004) and reported in medulloblastoma (Broderick et al. 2004), their role 
in tumorigenesis remains controversial. In particular it is not known if these mutations 
initiate or progress cancer. 
Math1-creERT2::Pik3caFl/+ and Math1-creERT2::Pik3caFl/Fl mice were induced at P3 and 
analysed. No abnormalities in brain development, no tumor development or 
abnormalities in survival could be observed. 
Analogous to the previous mouse model, mice with an additional constitutive activated 
form of PIK3CA were generated. Tumor incidence after tamoxifen administration was 
100%. Math1-creERT2::lsl-SmoM2Fl/+ lsl-Pik3caFl/+ mice showed a faster tumor 
development and first symptoms (e.g. head growth or ataxia) occurred earlier compared 
to Math1-creERT2::lsl-SmoM2Fl/+ mice (Figure 6). Kaplan-Meier analysis of these two 
mouse models show that mice with both (SMO and PIK3CA) mutations have a significantly 
(p < 0.0001) worse survival rate than mice with only a SMO mutation. The median survival 
of Math1-creERT2::lsl-SmoM2Fl/+ lsl-Pik3caFl/+ mice is 48 days. All tumors display classic 
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histology (Supplementary Figure 25). MBs in this mouse strain often have contact to the 
brainstem (13/18) (e.g. Figure 6 j, k). 
Here, heterozygous as well as homozygous PIK3CA mutations alone are not enough to 
generate a tumor in our mouse model, but leads to a faster tumor progression in Math1-
creERT2::lsl-SmoM2Fl/+ mice. 
Figure 6 (a-l) shows an overview of Math1-creERT2::lsl-SmoM2Fl/+, Math1-
creERT2::Pik3caFl/+, Math1-creERT2::Pik3caFl/Fl and Math1-creERT2::lsl-SmoM2Fl/+ lsl-
Pik3caFl/+ mice: sagittal section H&E and proliferation (Ki67). 
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Figure 6 Overview Math1-creERT2::lsl-SmoM2Fl/+, Math1-creERT2::lsl-Pik3caFl/+, Math1-creERT2::lsl-Pik3caFl/Fl 
and Math1-creERT2::lsl-SmoM2Fl/+ lsl-Pik3caFl/+ mice. Mice were induced with Tamoxifen at P3 and sacrificed 
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at P30. Left column (a, d, g, j) shows sagittal H&E stains of the whole brain (scale bar 1 mm), middle column 
(b, e, h, k) shows proliferation (Ki67 stains) of the cerebellum (scale bar 500 µm); Scale bar is 10 µm for 
higher magnifications (c, f, I, l). The Kaplan-Meier analysis (m) shows a sig. lower survival rate for Math1-
creERT2::lsl-SmoM2Fl/+ lsl-Pik3ca Fl/+  mice (n = 18) compared to Math1-creERT2::lsl-SmoM2Fl/+ mice (n = 25) 
(p < 0.0001). No Math1-creERT2::lsl-Pik3caFl/+ (n = 17) or Math1-creERT2::lsl-Pik3caFl/Fl (n = 5) mice died 
because of any symptoms. 
 
3.1.3 Mouse model with PTCH1 mutation 
 
Math1-creERT2::Ptch1Fl/Fl mice show after administration of tamoxifen in all Math1-
positive cells and their progeny a homozygous deletion of the Ptch1 gene and a 
constitutive activation of the SHH pathway. Depending on the time of tamoxifen 
administration these mice can develop medulloblastoma. Administration between 
embryonic day E14.5 and postnatal day P8 leads to a tumor incidence of 100% (Yang et 
al. 2008). The median survival of Math1-creERT2::Ptch1Fl/Fl mice is 127 days (Figure 7m). 
All tumors display classic histology (Supplementary Figure 25). 
Heterozygous deletion (Tamoxifen induction at P3) of the Ptch1 gene (Math1-
creERT2::Ptch1Fl/+) has no effect on brain development, there is no tumor formation and 
no abnormalities in survival could be observed (Figure 7). 
 
3.1.4 Mouse model with PTCH1 and PIK3CA mutations 
 
In a sequencing study of Robinson and collegues (Robinson et al. 2012) the identification 
of the co-occurrence of mutations in PTCH1 and PIK3CA in medulloblastoma was first 
described. 
Analogous to the previous mouse model, mice with an additional constitutive activated 
form of PIK3CA were generated. Math1-creERT2::Ptch1Fl/Fl lsl-Pik3caFl/+ and Math1-
creERT2::Ptch1Fl/Fl lsl-Pik3caFl/Fl mice showed a faster tumor development compared to 
Math1-creERT2::Ptch1Fl/Fl mice. Math1-creERT2::Ptch1Fl/Fl lsl-Pik3caFl/+ and Math1-
creERT2::Ptch1Fl/Fl lsl-Pik3caFl/Fl mice showed no differences in survival. Kaplan-Meier 
analysis show that mice with both (Ptch1Fl/Fl and PIK3CA) mutations have a worse survival 
rate than mice with only a Ptch1Fl/Fl mutation (Figure 7). Heterozygous or homozygous 
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mutation of PIK3CA alone under the Math1 promoter has no effect on survival. All tumors 
display classic histology (Supplementary Figure 25). 
Heterozygous deletion of the Ptch1 gene and a simultaneous constitutive activated form 
of PIK3CA (homo- or herterozygous) (Math1-creERT2::Ptch1Fl/+ lsl-Pik3caFl/+ and Math1-
creERT2::Ptch1Fl/+ lsl-Pik3caFl/Fl) has no effect on survival rate and did not show any 
symptoms of tumor development. 
Figure 7 (a-l) shows an overview of Math1-creERT2::Ptch1Fl/+, Math1-creERT2::Ptch1Fl/Fl, 
Math1-creERT2::Ptch1Fl/Fl lsl-Pik3caFl/+ and Math1-creERT2::Ptch1Fl/Fl lsl-Pik3caFl/Fl mice: 
sagittal section H&E and proliferation (Ki67). 
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Figure 7 Overview Math1-creERT2::Ptch1Fl/+, Math1-creERT2::Ptch1Fl/Fl,  Math1-creERT2::Ptch1Fl/Fl lsl-
Pik3caFl/+, Math1-creERT2::Ptch1Fl/Fl lsl-Pik3caFl/Fl, Math1-creERT2::lsl-Pik3caFl/+ and  Math1-creERT2::lsl-
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Pik3caFl/Fl mice. Mice were induced with Tamoxifen at P3 and sacrificed at P30. Left column (a, d, g, j) shows 
sagittal H&E stains of the whole brain (scale bar 1 mm), middle column (b, e, h, k) shows proliferation (Ki67 
stains) of the cerebellum (scale bar 500 µm) and right column shows higher magnification of Ki67 stains (c, 
f, i, l) (scale bar 10 µm). The Kaplan-Meier analysis (m) shows a sig. lower survival rate for Math1-
creERT2::Ptch1Fl/Fl lsl-Pik3caFl/+ (p = 0.0040; n = 5), Math1-creERT2::Ptch1Fl/Fl lsl-Pik3caFl/Fl (p = 0.0005; n = 5) 
compared to Math1-creERT2::Ptch1Fl/Fl mice (p < 0.0001; n = 6). No Math1-creERT2:: lsl-Pik3caFl/+ (n = 17) or 
Math1-creERT2:: lsl-Pik3caFl/Fl (n = 5) mice died because of any symptoms. 
 
3.1.5 Mouse model with MYCN amplification 
 
A number of observations suggest a role for the proto-oncogene MYCN in the pathogenesis 
of MB. Amplification of MYCN, a relatively rare event in MB, correlates with poor outcome 
(Pfister et al. 2009). Shh promotes the expression and post-transcriptional stabilization 
of N-Myc in mice (Kenney et al. 2003, Thomas et al. 2009). Brain-specific deletion of 
murine N-myc results in cerebellar dysplasia, suggesting that N-myc is critical to 
proliferation in the developing cerebellum, and that other myc family members cannot 
compensate for loss of N-myc (Knoepfler et al. 2002). Experiments in genetically 
engineered mice demonstrate that N-myc is required for MB development (Hatton et al. 
2006), suggesting that human tumors could also arise, in part, through misexpression of 
MYCN (Kenney et al. 2003, Oliver et al. 2003, Hatton et al. 2006, Kessler et al. 2009, 
Thomas et al. 2009). To date, however, N-myc overexpression (alone or in combination 
with Gli1, IGF-II, or Bcl-2) has failed to initiate MB in any experimental model (Browd et 
al. 2006, McCall et al. 2007). 
In this work Math1-creERT2::lsl-NmycFl/+ and Math1-creERT2::lsl-NmycFl/Fl were generated  
These mouse strains enable an overexpression of Nmyc in cerebellar granule precursors 
after administration of tamoxifen (at P5). This overexpression did not lead to any tumor 
formation in our mice (Figure 8) and no symptoms or other abnormalities in the brain 
could be observed. 
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3.1.6 Mouse model with MYCN amplification and TP53 mutation 
 
The TP53 gene provides instructions for making a protein called tumor protein p53 (or 
p53). This protein acts as a tumor suppressor, which means that it regulates cell division 
by keeping cells from growing and dividing too fast or in an uncontrolled way. 
Combined MYC family amplifications and P53 pathway defects (TP53 mutation) 
commonly emerged at relapse, and all patients in this group died of rapidly progressive 
disease postrelapse (Hill et al. 2015). These clinical observations and previous modelling 
of medulloblastoma in mice suggested that aberrant activation of the MYC gene family 
synergizes with inactivation of p53 or Rb in the genesis of biologically aggressive 
medulloblastoma (Shakhova et al. 2006, Kawauchi et al. 2012, Pei et al. 2012). 
For this project mouse strains with an overexpression on Nmyc and a simultaneous p53 
loss of function in cerebellar granule precursors after administration of tamoxifen (at P5) 
were generated (Math1-creERT2::lsl-NmycFl/+p53Fl/+, Math1-creERT2::lsl-NmycFl/+p53Fl/Fl, 
Math1-creERT2::lsl-NmycFl/Flp53Fl/+ and Math1-creERT2::lsl-NmycFl/Flp53Fl/Fl mice). Mice 
with only a p53 loss of function (hetero- and homozygous) were completely 
inconspicuous.  
Recently, the group of Wechsler-Reya developed a similar mouse model with MYCN 
amplifications. These mice did not develop medulloblastoma, but they developed choroid 
plexus tumors (personal communication). These tumors arise from brain tissue called the 
“choroid plexus.” They commonly invade nearby tissue and spread widely via the 
cerebrospinal fluid. Due to this information we also looked at the choroid plexus. 
All these mouse models did neither develop a tumor in the cerebellum, nor abnormalities 
could be found in the choroid plexus of these animals (Figure 8).  
Figure 8 shows an overview of the different genotypes of sagittal sections H&E and 
proliferation (Ki67). 
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Figure 8 Overview Math1-creERT2::lsl-NmycFl/+, Math1-creERT2::lsl-NmycFl/Fl, Math1-creERT2::p53Fl/+, Math1-
creERT2::p53Fl/Fl, Math1-creERT2::lsl-NmycFl/+p53Fl/+, Math1-creERT2::lsl-NmycFl/+p53Fl/Fl, Math1-creERT2::lsl-
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NmycFl/Flp53Fl/+ and Math1-creERT2::lsl-NmycFl/Flp53Fl/Fl mice. All mice were induced with Tamoxifen at P5 
and sacrificed at P70. Left column (a, d, g, j, m, p, s, v) shows sagittal H&E stains of the whole brain (scale 
bar 1 mm), right column shows proliferation (Ki67 stains) of the cerebellum (b, e, h, k, n, q, t, w) (scale bar 
500 µm) and choroid plexus (c, f, I, l, o, r, u, x.) (scale bar 200 µm). 
 
Survival analysis for Math1-creERT2::lsl-NmycFl/+ (n = 22), Math1-creERT2::lsl-NmycFl/Fl (n = 
11), Math1-creERT2::p53Fl/+ (n = 9), Math1-creERT2::p53Fl/Fl (n = 8), Math1-creERT2::lsl-
NmycFl/+p53Fl/+ (n = 12), Math1-creERT2::lsl-NmycFl/+p53Fl/Fl (n = 2), Math1-creERT2::lsl-
NmycFl/Flp53Fl/+ (n = 11) and Math1-creERT2::lsl-NmycFl/Flp53Fl/Fl (n = 4) mice shows no 
significant difference in prognosis over the different genotypes (Figure 9). 
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Figure 9 Kaplan-Meier analysis for Math1-creERT2::lsl-NmycFl/+ (n = 22), Math1-creERT2::lsl-NmycFl/Fl (n = 11), 
Math1-creERT2::p53Fl/+ (n = 9), Math1-creERT2::p53Fl/Fl (n = 8), Math1-creERT2::lsl-NmycFl/+p53Fl/+ (n = 12), 
Math1-creERT2::lsl-NmycFl/+p53Fl/Fl (n = 2), Math1-creERT2::lsl-NmycFl/Flp53Fl/+ (n = 11) and Math1-
creERT2::lsl-NmycFl/Flp53Fl/Fl (n = 4) mice. 
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3.2 Localization of SHH medulloblastoma in mice depends on the age 
at its initiation 
 
Approximately, 30% of MBs belong to the SHH subgroup. This subgroup shows a two-
peak age distribution, making up the majority of infant (≤ 3 years) and adult (≥ 16 years) 
MBs, but only a small fraction of childhood (4-15 years) tumors (Kool et al. 2012). Global 
methylation and gene expression profiles of infant and adult SHH MBs are clearly distinct, 
although, overall, they belong to the same molecular subgroup (Northcott et al. 2011, Kool 
et al. 2014). In addition, localization of human SHH MBs differs depending on the age of 
the patient. For so far unknown reasons, adult SHH MBs are almost exclusively located in 
cerebellar hemispheres, whereas infant SHH MBs often grow in the vermis (Wefers et al. 
2014). Since the genetic makeup is known to be different in infant and adult MB (Kool et 
al. 2014), it appears possible that the anatomical localization is dependent on the tumor’s 
driver mutations. On the other hand, it appears possible that the susceptibility of different 
cell types for oncogenic transformation is dependent on a distinct developmental time 
frame, but independent of the tumor-initiating driver mutation. To test this hypothesis in 
a systematic way, we used Math1-GFP,Ptc+/− mice, which develop green fluorescent SHH 
MB (Goodrich et al. 1997, Oliver et al. 2005). Importantly, in contrast to SUFU or SMO 
mutations that predominantly occur in SHH MB of infants and adults, respectively, PTCH1 
mutations are equally detected in both age groups of human SHH MB (Kool et al. 2014, 
Pöschl et al. 2014). So, PTCH1 mutations per se do not appear to predispose for a specific 
tumor localization. 
First, we analysed the localization of Math1-GFP,Ptc+/− MBs in the cerebellum at different 
time points. The localization of a tumor (as defined as >2 mm in size) was categorized 
according to the involvement of vermis and hemispheres, the involvement of rostral and 
caudal cerebellar regions, and its growth into the fourth ventricle (Figure 10). 
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Figure 10 Anatomical compartments of the murine cerebellum. 
 
We confirmed expression of Sox2 in all tumors that were included in our statistics, as 
preneoplastic lesions and real tumors have quite different gene expression profiles, and 
Sox2 is at the top of the list of the genes that are expressed in tumors, but not in normal 
granule cell precursors or preneoplastic lesions (Oliver et al. 2005) (Figure 11). 
 
 
Figure 11 Sox2 expression in Math1-GFP,Ptc+/- mice. (a) Sox2 expression is not detectable in small 
preneoplastic lesions of Math1-GFP,Ptc+/- mice. (b) On the contrary, large tumors that are visible in older 
mice display strong Sox2 expression. 
 
We analysed 81 5-week-old and 34 10-week-old Math1-GFP,Ptc+/− mice (Figure 13a). In 
the 5-week-old group, 44/81 animals (54%) had no MB, 23/81 (29%) developed one 
tumor, 13/81 (16%) developed two separable tumors, and 1/81 (1%) developed three 
separable tumors within the cerebellum. Only 7/34 animals (20%) in the 10-week-old 
group did not develop any MB, 4/34 (12%) had 2 separable tumors, and 23/34 (68%) 
developed one tumor (p < 0.001). Hence, the overall tumor incidence was 46 % in 5-week-
old mice and 80% in 10-week-old mice. This implies that a good number of tumors 
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develop after 5 weeks of age. Representative examples of MB in 5- or 10-week-old Math1-
GFP,Ptc+/− mice are given in Figure 12. 
 
 
Figure 12 Representative fluorescent images and H&E stains of MB in Math1-GFP,Ptc+/- mice at different 
time points. Arrows point to tumors, which display classic histology at both ages. High magnifications are 
shown on the right. Scale bars correspond to 2 mm for low-power images and 10 µm for high-power images. 
 
Every tumor was then categorized according to its main localization in the cerebellum 
(Figure 13 b). 31/52 MBs of the 5-week-old Math1-GFP,Ptc+/− mice (60 %) exclusively 
grew in the hemispheres, but 9/52 tumors (17 %) were restricted to the vermis. In 
contrast, all 31 tumors in the 10-week-old group grew in the hemispheres with 15/31 (48 
%) being exclusively in the hemispheres (p < 0.01). This implies that tumors in the vermis 
do not develop at later stages and must develop in embryonic or early postnatal stages. 
Otherwise, one would clearly expect MBs that exclusively occupy the vermis at 10 weeks 
of age (Ohli et al. 2015). 
Furthermore, we analysed the main vertical MB localization (Figure 13 c). 
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Figure 13 (a) MB incidence in Math1-GFP,Ptc+/- mice. (b) Main localization in the cerebellum of Math1-
GFP,Ptc+/- mice. (c) Main vertical MB localization. (d) Ventricle relation of MB. 
 
Almost half of the tumors of the 5-week-old mice (25/52, 48%) grew only caudal, whereas 
only 11/52 (21%) grew exclusively rostral. In the 10-week old group, 8/31 (26%) grew 
only caudal, 2/31 (6%) grew only rostral, but the majority of these tumors extended 
rostro-caudal (21/31, 68%) (p < 0.01). Moreover, 6/52 (12%) of the 5-week-old MBs and 
10/31 (32%) of the 10-week old MBs expanded into the fourth ventricle (Figure 13 d, p = 
0.02). 
To confirm the time-dependent localization of SHH medulloblastoma in an independent 
model, we used Math1-creERT2::lsl-SmoM2Fl/+ mice that were Tamoxifen-induced at E14.5 
or P5. To make sure that the targeted cells under both conditions are comparable, we first 
performed lineage tracing analyses using Math1-creERT2::tdTomato mice and found an 
equal distribution of creERT2-mediated recombination, as indicated by RFP staining 
throughout the vermis and the hemispheres for both time points of Tamoxifen induction 
(Figure 14 a). Therefore mice from the Math1-creERT2 strain were paired with mice which 
carry a sequence for a red fluorescent protein (tdTomato, variant of RFP). With the Cre-
LoxP-system it is possible through, the cre-mediated recombination, to cut out specific 
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sequences lying between two loxP-sequences. In the system used here, the sequence 
which is cut out is a polyadenylation sequence, thus a stop-codon. After the loss of the 
stop-codon, the expression of the coding reporter genes could take place. This induced 
modification in the protein expression also manifest after the cell divison and 
independent of further differentiation of progeny. Thus, every daughter cell of a primary 
recombinated cell further on express RFP. Due to the traceability of the fate of a single cell 
and populations with this system, it is called fate-mapping or lineage tracing analysis.  
Tumor growth in Math1-creERT2::lsl-SmoM2Fl/+ mice was then analysed in the vermis and 
hemispheres at P14 or P26, i.e., 3 weeks after Tamoxifen induction (Figure 14 b). In 
agreement with the data above, we did not find anatomical differences in the tumor 
growth when induced at E14.5. However, animals induced postnatally (P5) developed 
tumors, the growth of which was clearly pronounced in the hemispheres (Figure 14 c). 
There was significantly less tumor burden in the vermis of P5-induced animals compared 
to embryonically induced mice. Together, these results fit well to the distribution of SHH 
MBs in humans (Wefers et al. 2014) and indicate that the localization of SHH MBs is 
dependent on the time-restricted susceptibility of granule cell precursors in defined 
cerebellar compartments, and independent of the type of tumor-initiating driver 
mutation.  
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Figure 14 (a) RFP stainings indicating equally distributed recombination in granule cells of Math1-
creERT2::tdTomato mice. (b) H&E stainings of embryonically and postnatally induced Math1-creERT2::lsl-
SmoM2Fl/+ mice. Arrows indicate tumor areas in the vermis and hemisphere. (c) Quantification of the relative 
tumor area of embryonically and postnatally induced Math1-creERT2::lsl-SmoM2Fl/+ mice in different 
cerebellar compartments. Scale bars correspond to 2 mm for low-power image (right image in a and both 
images in b), 500 µm (left image in a).  Bars show mean with SEM. ns not significant, ** p < 0.01, *** p < 
0.001. 
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3.3 Effects of Wnt/β‑catenin signalling on Shh‑dependent 
medulloblastoma formation 
 
Shh is crucial for the proliferation of cerebellar granule neuron precursors (GNPs) 
(Wechsler-Reya and Scott 1999), but constitutive activation of the Shh pathway in GNPs 
leads to medulloblastoma (Schüller et al. 2008). In contrast, canonical Wnt/ß-catenin 
signalling is required for the maturation of GNPs, and constitutive activation of this 
pathway causes significant proliferation deficits (Lorenz et al. 2011). To develop new 
therapeutic strategies for patients with Shh-medulloblastoma, we asked whether the 
physiological roles of Wnt/ß-catenin signalling can be utilized to treat Shh-
medulloblastomas that have developed from GNPs. 
To analyse the effect of Wnt/ß-catenin-activation, primary cell culture experiments were 
performed. At the time point of the biggest clonal expansion of the granule cell precursors 
(p5-p7) the Shh-activating SmoM2-mutation and the Wnt-activating form of ß-catenin 
were introduced by viral inserted cre-recombinase. SmoM2Fl/+, Ctnnb1(ex3)Fl/+, or 
SmoM2Fl/+ Ctnnb1(ex3)Fl/+ cerebellar GNPs were cultured as described (Lorenz et al. 2011) 
and transduced with Cre-IRES-GFP viruses. Cre treatment of SmoM2Fl/+ cerebellar GNPs 
led to a 2.6-fold proliferation increase due to active Shh signalling (Figure 15, p = 0.008). 
Here, proliferation is the fraction of BrdU+ cells among GFP+ granule cells [%]. 
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Figure 15 Cultured cerebellar GNPs from mice of indicated genotypes were transduced with control IRES-
GFP virus or Cre-IRES-GFP virus to recombine alleles. Wnt/ß-catenin-activation significantly reduced 
proliferation of both normal GNPs and SmoM2Fl/+ -transformed GNPs. Bars show mean with SEM. ns not 
significant. * p < 0.05, ** p < 0.01. 
 
Wnt pathway activation in Ctnnb1(ex3)Fl/+ GNPs reduced proliferation to 52% (Figure 15, 
p = 0.029). Importantly, Wnt-activation significantly decreased oncogenic GNP 
proliferation driven by SmoM2 (SmoM2Fl/+ Ctnnb1(ex3)Fl/+ condition, p = 0.028), and cells 
reached proliferation levels similar to the wild type. Thus, the proliferation of Shh-
medulloblastoma cells may be blocked through canonical Wnt signalling. These results 
extend previous studies showing inhibitory effects of Wnt3a through non-canonical Wnt 
signalling on GNPs (Anne et al. 2013). 
Next, we introduced a Ctnnb1(ex3)Fl/+ allele into Math1-cre::SmoM2Fl/+ mice, a model for 
Shh-medulloblastoma (Schüller et al. 2008). Activation of the Shh pathway in Math1-
positive GNPs resulted in a thickened external granule cell layer (EGL) and 
medulloblastoma (Figure 16 a, b; Supplementary Figure 26). Additional activation of the 
Wnt-pathway (Math1-cre::SmoM2Fl/+Ctnnb1(ex3)Fl/+ mice) notably reduced growth of 
medulloblastoma and resulted in decreased cerebellar size (Figure 16 a, c; Supplementary 
Figure 26). Importantly, Math1-cre::SmoM2Fl/+Ctnnb1(ex3)Fl/+ mice (n = 16) survived 
significantly longer than Math1-cre::SmoM2Fl/+ animals (n = 53, p < 0.0001, (Figure 16 d)).  
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Figure 16 (a-c) Sagittal cerebellar sections. Shh pathway activation in Math1-positive cerebellar GNPs 
resulted in the formation of medulloblastoma (b). Co-activation of the Wnt/β-catenin signalling pathway 
[Math1-cre::SmoM2Fl/+Ctnnb1(ex3)Fl/+ mice] reduced growth of medulloblastoma and led to a decreased 
cerebellar size (c). (d) Math1-cre::SmoM2Fl/+Ctnnb1(ex3)Fl/+ mice displayed a significantly prolonged 
survival. ML molecular layer, PL Purkinje cell layer, IGL internal granule cell layer 
 
In order to just analyse cells, that were transduced with Cre-IRES-GFP virus, we used FACS 
(fluorescence-activated cell sorting) to isolate GFP+ cells from SmoM2Fl/+ or 
SmoM2Fl/+Ctnnb1(ex3)Fl/+ GNP cultures after Cre-IRES-GFP virus treatment. Looking at 
different targets of the Shh and the Wnt pathway, quantitative RT-PCR analysis was 
performed. It could be confirmed that the mRNA level of Axin2, a direct target of the Wnt 
pathway, was upregulated in SmoM2Fl/+Ctnnb1(ex3)Fl/+ GNPs, whereas the mRNA level of 
Gli1, a downstream target of the Shh pathway, was downregulated (Figure 17). 
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Figure 17 Relative quantification of Axin2 and Gli1 in GFP+ SmoM2Fl/+ and SmoM2Fl/+Ctnnb1(ex3)Fl/+ GNPs 
after Cre-IRES-GFP transduction. Bars show mean with SEM. 
 
Hence, active canonical Wnt signalling is a potent inhibitor of the Shh pathway in 
medulloblastoma. Pharmacologically, activation of Wnt/β-catenin signalling can be 
achieved via inhibition of GSK3β, an upstream player of the pathway (Rubinfeld et al. 
1996). Primary cell culture was used for cre treatment of cerebellar GSK3βFl/Fl GNPs 
(Jaworski et al. 2011). A significant decrease in proliferation was achieved when GSK3ß 
was knocked out in vitro (Figure 18, p = 0.041). 
 
 
Figure 18 GSK3ß knockout resulted in significantly reduced proliferation of GNPs. (a) Cultured cerebellar 
granule neuron precursors (GNPs) from GSK3ß mice (P5-P7) were transduced with IRES-GFP (control) and 
Cre-IRES-GFP virus to recombine alleles. GFP staining (green) shows recombined cells, BrdU staining (red) 
shows proliferating cells. Knockout of GSK3ß led to decreased proliferation of transduced cerebellar GNPs 
(arrows point to proliferating cells that have undergone successful recombination).(b) Quantifications for 
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results shown in (a) including control experiments with IRES-GFP virus. Bars show mean of three individual 
experiments. Knockout of GSK3ß significantly reduced proliferation of cerebellar GNPs (p = 0.041). Bars 
show mean with SEM. ns not significant, * p < 0.05 (t-test). 
 
3.3.1 In vitro treatment with the Wnt agonist lithium chloride 
 
Lithium is a chemical element with psychotropic properties, which is commonly used to 
treat bipolar disorder as well as other psychiatric diseases (Geddes et al. 2004, Storosum 
et al. 2007), although the underpinnings of its biochemical effects remain only partially 
understood (Alda 2015). Among others, Lithium has been shown to act as an inhibitor of 
Glycogen synthase kinase 3 beta, a serine/threonine kinase also known as GSK3B (Klein 
and Melton 1996, Stambolic et al. 1996, O'Brien and Klein 2009). GSK3B is part of the so-
called cytoplasmic destruction complex together with Axin, Adenomatosis polyposis coli 
(APC), Dishevelled (Dvl), the CK1-Kinase group and GSK3A (Clevers 2006). This protein 
complex leads to phosphorylation, ubiquitination, and therefore proteasomal 
degradation of β-Catenin in the cytoplasm (Aberle et al. 1997, Willert et al. 1999). Hence, 
Lithium is able to activate the Wnt/ β-Catenin pathway by inhibiting GSK3B and therefore 
preventing phosphorylation and subsequent degradation of β-Catenin (Stambolic et al. 
1996). Previous results demonstrated an inhibitory effect of constitutional Wnt/ β-
Catenin activation on Shh-dependent medulloblastoma formation in Math1-
cre::SmoM2Fl/+::Ctnnb1(ex3)Fl/+ mice (Pöschl et al. 2014). In order to examine, whether a 
Wnt agonist might represent a suitable treatment option for patients with Shh-dependent 
medulloblastoma, a series of in vitro experiments was conducted, in order to inquire a 
possible inhibitory effect of lithium chloride (LiCl), a highly soluble lithium salt, which has 
been suggested to act as a Wnt/ β-Catenin activator in the cerebellum (Lancaster et al. 
2011). MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assays were 
carried out to investigate, whether the treatment of medulloblastoma tumor cells with 
LiCl would result in a decrease of cell viability in vitro (Figure 19).  
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Figure 19 Lithium chloride (LiCl) reduces medulloblastoma cell viability in vitro. Colorimetric MTT assays 
after 24h in vitro treatment with 10 mM LiCl decreased cell viability of granule neuron precursor cells and 
medulloblastoma tumor cells from Math1-cre::SmoM2Fl/+ and Ptch1+/- mice, when compared to HEK293T, 
UW473 and GL261 control cells. p < 0.01, t-test. Bars show mean with SEM. ns not significant. ** p < 0.01. 
 
Granule neuron precursor cells (GNPs), from which Shh-dependent medulloblastoma 
arise (Schüller et al. 2008), as well as medulloblastoma tumor cells from Math1-
cre::SmoM2Fl/+ and Ptch1+/- mice, two well-known murine models for Shh-induced 
medulloblastoma (Goodrich et al. 1997, Schüller et al. 2008), were isolated and put into 
primary culture for 16 hours. These cells were than treated with 10 mM LiCl for 24 hours 
in parallel with the fibroblast line HEK293T, the (non-SHH) medulloblastoma cell line 
UW473 and the glioma cell line GL261 cell lines, which served as Shh-independent control 
cells. As a result, LiCl lead to a significant decrease of cell viability in Shh-dependent GNPs 
and tumor cells from Math1-cre::SmoM2Fl/+ and Ptch1+/- mice when compared to control 
cells (p < 0.01) (Figure 19). Thus, LiCl is able to inhibit proliferation of Shh-associated 
medulloblastoma cells in vitro.  
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3.4 Preclinical treatment of mouse models of SHH medulloblastoma 
with Hh inhibitors 
 
 
Figure 20 Overview over treatment of Shh-associated mouse models. Using CreERT2 systems, 
recombination will be induced by a single i.p. shot of 1 mg Tamoxifen at postnatal day 3 or 5. The inducible 
conditional transgenic mice will receive primary treatment starting at day 30 using LDE225 (30 mg/kg/day 
i.p., 5 days per week, treatment duration 21 days). Once mice become symptomatic they will be sacrificed. 
One half of the brain will be processed for histology and tumor tissue will be harvested from the other 
second half for molecular analyses. Tumor samples with and without LDE225 treatment will be analysed 
and compared. 
 
Targeted therapies as a novel treatment modality for MB patients are especially intriguing 
for primary and relapsed SHH-MB. As more drugs targeting the Hh pathway become 
available and enter clinical trials, it is important to know how to stratify the patients for 
different drugs in order to maximize response rates and to prevent unnecessary 
treatment failures. 
Mouse models for medulloblastoma can be treated with SMO inhibitors that have already 
entered clinical trials and drugs targeting at the level of GLI, such as arsenic trioxide 
(ATO), bromodomain inhibitors like JQ1 or other more recently developed specific GLI 
inhibitors, such as GANT61. 
Transgenic mice are induced with tamoxifen and then randomly divided in two groups 
(vehicle/with treatment). After tumor development, mice were sacrificed und tumor 
tissue was harvested for molecular analyses (Figure 20). 
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3.4.1 LDE225 treatment 
 
Here we focus on the SMO antagonist LDE225. LDE225 (also known as Sonidegib; 
Novartis Pharma) is as synthetic, highly potent and selective, small molecule clinical SMO 
inhibitor resulting from the optimisation as a hit arising from a high throughput screening 
phenotypic assay designed to identify SMO inhibitors. LDE225 interacts directly with 
SMO, in a similar fashion to cyclopamine, to reduce expression of downstream Hh 
signalling targets (Pan et al. 2010). LDE225 is effective in various Hh-dependent tumor 
models and inhibits downstream expression of Hh targets in cell lines, in vivo animal 
models and in patients, and is currently under clinical trial investigation both as a single 
agent (Rodon et al. 2014) and in combination (reviewed in (Brechbiel et al. 2014)). 
All mice are monitored for treatment response, development of resistance, and overall 
survival. 
 
3.4.1.1 LDE225 treatment in Math1-creERT2::lsl-
SmoM2Fl/+ mice 
 
To determine the effects of LDE225 treatment on tumor growth in vivo, Math1-
creERT2::lsl-SmoM2Fl/+ mice at P30 were randomized to receive either vehicle or LDE225 
(30 mg/kg/day) five times per week for three weeks and assessed for tumor 
development. Tumor size was substantially reduced in LDE225-treated Math1-
creERT2::lsl-SmoM2Fl/+ mice compared to the control condition. LDE225 treatment 
resulted in a significantly extended lifespan of Math1-creERT2::lsl-SmoM2Fl/+ mice (Figure 
21 a). After three weeks of LDE225 treatment there is a significant reduction in 
proliferation or BrdU+ cells in LDE225-treated tumors of Math1-creERT2::lsl-SmoM2Fl/+ 
mice (Figure 21 b). There is no change in morphology after treatment compared to 
untreated Math1-creERT2::lsl-SmoM2Fl/+ tumors (data not shown). 
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Figure 21 (a) Kaplan-Meier survival curve illustrating overall survival of Math1-creERT2::lsl-SmoM2Fl/+ mice 
in LDE225 treatment cohort. All mice were induced to tumor formation at P3 by tamoxifen and treated with 
vehicle or LDE225 from P30 to P51. LDE225 treatment leads to a significant improvement of survival rate 
(log rank test, p < 0.0001); (b) Quantification of the fraction of BrdU+ tumor cells at P51 in Math1-
creERT2::lsl-SmoM2Fl/+ mice treated with vehicle or LDE225 for 21 days (n = 3, mean ± SEM, t-test), scale bar 
20 µm. *** p < 0.001. 
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3.4.1.2 LDE225 treatment in Math1-creERT2::lsl-
SmoM2Fl/+ lsl-Pik3caFl/+ mice 
 
 
Figure 22 Comparison of Math1-creERT2::lsl-SmoM2Fl/+ and Math1-creERT2::lsl-SmoM2Fl/+ lsl-Pik3caFl/+ mice. 
H&E (a, c) scale bar 1 mm; Ki67 (b, d) scale bar 500 µm. 
 
To determine the effects of LDE225 treatment on tumor growth in a similar mouse model 
(described above) with an additional mutation in Pik3ca, Math1-creERT2::lsl-SmoM2Fl/+ lsl-
Pik3caFl/+ mice were treated in a similar way like Math1-creERT2::lsl-SmoM2Fl/+ mice. As 
Math1-creERT2::lsl-SmoM2Fl/+ lsl-Pik3caFl/+ mice had a lower median survival and much 
faster tumor growth than Math1-creERT2::lsl-SmoM2Fl/+ mice, Math1-creERT2::lsl-
SmoM2Fl/+ lsl-Pik3caFl/+ mice often died during the 3 week long treatment phase. Therefore 
treatment start was moved up from P30 to P20 (Figure 22). As first symptoms normally 
occurred around P20 in Math1-creERT2::lsl-SmoM2Fl/+ lsl-Pik3caFl/+ mice and in Math1-
creERT2::lsl-SmoM2Fl/+ mice around P30, this shifted time point of treatment start makes 
the treatment of this two mouse strains more comparable (Figure 22). Both treatment 
groups had no significant improvement of survival compared to the control group. 
However, Math1-creERT2::lsl-SmoM2Fl/+ lsl-Pik3caFl/+ mice with an earlier treatment start 
(P20) have a better prognosis than Math1-creERT2::lsl-SmoM2Fl/+ lsl-Pik3caFl/+ mice with a 
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later treatment start (P30) (p = 0.0065)(Figure 23 a). However, after three weeks of 
LDE225 treatment there is a significant reduction in BrdU+ cells in LDE225-treated 
tumors of Math1-creERT2::lsl-SmoM2Fl/+ lsl-Pik3caFl/+ mice with treatment start at P20 as 
well as with treatment start at P30 compared to the control group (Figure 23 b). LDE225 
treatment does not change the morphology of Math1-creERT2::lsl-SmoM2Fl/+ lsl-Pik3caFl/+ 
tumors compared to untreated tumors (data not shown). 
 
 
Figure 23 (a) Kaplan-Meier survival curve illustrating overall survival of Math1-creERT2::lsl-SmoM2Fl/+ lsl-
Pik3caFl/+ mice in LDE225 treatment cohort. All mice were induced to tumor formation at P3 by tamoxifen 
and treated with vehicle or LDE225 from P30 to P51 or P20 to P41. Math1-creERT2::lsl-SmoM2Fl/+ lsl-
Pik3caFl/+ LDE225 (treatment start P20) (n = 10) vs Math1-creERT2::lsl-SmoM2Fl/+ lsl-Pik3caFl/+ vehicle (n = 
13) (p = 0.0651); Math1-creERT2::lsl-SmoM2Fl/+ lsl-Pik3caFl/+ LDE225 (treatment start P30) (n = 9) vs Math1-
creERT2::lsl-SmoM2Fl/+ lsl-Pik3caFl/+ vehicle (n = 13) (p = 0.2982); Math1-creERT2::lsl-SmoM2Fl/+ lsl-Pik3caFl/+ 
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LDE225 (treatment start P20) (n = 10) vs Math1-creERT2::lsl-SmoM2Fl/+ lsl-Pik3caFl/+ LDE225 (treatment 
start P30) (n = 9) (p = 0.0065); (b) Quantification of the fraction of BrdU+ tumor cells at P51 (for vehicle and 
LDE225 (P30)) and at P41 (for LDE225 (P20)) in Math1-creERT2::lsl-SmoM2Fl/+ lsl-Pik3caFl/+ mice treated 
with vehicle or LDE225 for 21 days (n = 3, mean ± SEM, t-test), scale bar 20 µm. * p < 0.05, ** p < 0.01, *** p 
< 0.001. 
 
3.4.1.3 LDE225 treatment in Math1-
creERT2::Ptch1Fl/Fl mice  
 
This mouse strain was also treated with the same dosage (30 mg/kg/day) and duration 
(5 times per week, for 3 weeks) of LDE225. Here treatment start was P30. LDE225 
treatment leads to a significant better survival rate (p = 0.0198) compared to the control 
group (Figure 24 a). After three weeks of LDE225 treatment there is a significant 
reduction in BrdU+ cells in LDE225-treated tumors of Math1-creERT2::Ptch1Fl/Fl mice 
(Figure 24 b). The treatment has no effect on the morphology of Math1-creERT2::Ptch1Fl/Fl 
tumors compared to untreated tumors (data not shown). 
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Figure 24 (a) Kaplan-Meier survival curve illustrating overall survival of Math1-creERT2::Ptch1Fl/Fl mice in 
LDE225 treatment cohort. All mice were induced to tumor formation at P3 by tamoxifen and treated with 
vehicle or LDE225 from P30 to P51. Math1-creERT2::Ptch1Fl/Fl vehicle (n = 14) vs Math1-creERT2::Ptch1Fl/Fl 
LDE225 (n = 7) (p = 0.0198); (b) Quantification of the fraction of BrdU+ tumor cells at P51 in Math1-
creERT2::Ptch1Fl/Fl mice treated with vehicle or LDE225 for 21 days (n = 3, mean ± SEM, t-test), scale bar 20 
µm. *** p < 0.001. 
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4 Discussion 
 
MB is a collection of clinically and molecularly distinct tumor subgroups that arise either 
in the cerebellum or brainstem (Louis et al. 2007, Schüller et al. 2008, Grammel et al. 2012, 
Taylor et al. 2012). In children they comprise the most frequent embryonal brain tumor, 
whereas in adults the disease is relatively rare, accounting for about 1% of all intracranial 
malignancies (Louis et al. 2007). Current therapy regimens including surgery, cranio-
spinal radiotherapy, and chemotherapy, may cure 70-80% of patients with MB. Most 
survivors, however, suffer from long-term sequelae as a result of the intensive treatment, 
demonstrating that less toxic treatments are urgently needed. Molecular analyses have 
shown that there are four major MB subgroups (WNT, Sonic Hedgehog (SHH), Group 3, 
Group 4) (Taylor et al. 2012). But this is just a rough classification as a considerable 
amount of heterogeneity was already described within a single molecular subgroup. 
Specifically for human SHH-associated MB, differences on the molecular level and also in 
clinical parameters were described for infants and adult patients (Northcott et al. 2011). 
Curiously, Shh-MB occur in a bimodal distribution, making up the majority of infant (≤ 3 
years) and adult (≥ 16 years) MBs, but only a very small fraction of childhood (4-15 years) 
tumors. This unusual bimodal age distribution also suggests the existence of Shh-
subgroup heterogeneity. 
As targeted therapies for MB patients are novel strategies for treatment, this project 
focused on different mouse models for analysing Shh-associated MBs in more detail. 
 
4.1 Localization of SHH medulloblastoma in mice 
 
In order to unravel a possible relation between MB biology and localization, and to 
provide novel hints regarding the cellular origin of MB, Math1-GFP,Ptc+/- mice, which 
develop green fluorescent SHH MBs, were analysed regarding tumor localization. MB 
occurring in Ptc+/- mice or Smo-based mouse models resemble the human counterparty in 
an excellent manner (Pöschl et al. 2014). For so far unknown reasons, human adult SHH 
MBs are almost exclusively located in cerebellar hemispheres, whereas human infant SHH 
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MBs often grew in the vermis (Wefers et al. 2014). Here we show in mice that 60% of the 
younger group (5-week-old) had tumors that exclusively grew in the hemispheres, but 
17% were restricted to the vermis. In contrast, in the older group (10-week-old) all 
tumors grew in the hemispheres and no single tumor was restricted to the vermis (Figure 
13). This leads to the suggestion that tumors in the vermis do not develop at later stages 
and must develop in embryonic or early postnatal stages. Otherwise, one would clearly 
expect MBs that exclusively occupy the vermis also in the older group. To confirm the 
time-dependent localization of SHH MB, another Shh-associated mouse model (Math1-
creERT2::lsl-SmoM2Fl/+) was used (Figure 14). It could be demonstrated that there is less 
tumor burden in the vermis of postnatal-induced mice compared to embryonically 
induced mice. Using well established mouse models we showed here that oncogenic 
transformation of granule cell precursors at early developmental time points may result 
in the formation of midline and hemispheric medulloblastoma. On the other side, 
oncogenic transformation at later developmental time points exclusively results in the 
formation of hemispheric medulloblastoma. These results perfectly match to the recently 
published distribution of SHH MBs in humans (Wefers et al. 2014) and indicate that the 
localization of SHH MBs is dependent on the time-restricted susceptibility of granule cell 
precursors in defined cerebellar compartments, and independent of the type of tumor-
initiating driver mutation. 
The tumor incidence of the Math1-GFP,Ptc+/- mice used here was clearly higher as 
described before (Figure 13 a). The 5-week old group show a tumor incidence of 46% and 
10-week old mice 80%, whereas Oliver and colleagues only described a tumor incidence 
of 14-20% of patched heterozygotes (Oliver et al. 2005). The rather high incidence in this 
study here could be explained as it is known that the tumor incidence (and spectrum) in 
Ptc+/- mice may vary from colony to colony. 
The time point of tumor analysis (as for Math1-GFP,Ptc+/- mice) and tumor induction (as 
for Math1-creERT2::lsl-SmoM2Fl/+ mice) is a crucial point with some limitations. Apart from 
tumors that eventually develop, normal granule neuron precursors also express Math1 
and will hence shine green in Math1-GFP mice. Thus, mice with 3 weeks of age or even 
younger are not suited for our experiments, because granule neuron precursors are still 
present and one would detect green fluorescence all over the cerebellum. Furthermore, 
SHH MB occur either in infancy (predominantly in midline structures) or in adulthood 
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(predominantly in cerebellar hemispheres). 1 year in humans approximately corresponds 
to 3 weeks of age in mice (ten Donkelaar et al. 2006, Manto et al. 2013). While 3 weeks is 
too early for tumor analysis in mice, 5 weeks of age appears appropriate and still 
corresponds to human infancy. 10 weeks of age in mice were chosen, since this is well 
after mice become fertile, which corresponds to the age of 16-20 years of humans. This 
exactly covers the second peak of incidence for human SHH medulloblastoma. Mice older 
than 10 weeks of age appear inappropriate, since we would lose too many mice, which die 
between 10 and 20 weeks of age. Furthermore, tumors may have become huge, so that it 
is very hard, if not impossible to judge, whether a tumor started in the vermis or in one of 
the hemispheres. For the tamoxifen application in Math1-creERT2::lsl-SmoM2Fl/+ mice, 
there is a theoretical time frame between E14.5 and P8 with 100% tumor incidence (Yang 
et al. 2008). While it is very hard to estimate, at which time point tumor initiation occurs 
in humans, we thought that choosing time points for tamoxifen induction that are far away 
from each other would be good to detect any possible differences in tumor localization. 
 
4.2 Wnt/ß-catenin signalling and Shh-dependent medulloblastoma 
 
Survival of children with relapsed or refractory MB remains remarkably poor despite 
aggressive treatment protocols and cure is a rare exception for these patients (Jones et al. 
2012). This highlights the urgent medical need to identify and validate novel molecular 
targets that can be exploited for the treatment of these patients in order to improve their 
dismal prognosis. Since conventional therapies and risk stratification have already been 
optimized in recent years, molecular targeted therapies are currently considered to open 
promising perspectives for more efficient therapies. 
The SHH pathway interacts with different other pathways. The Wnt/beta-catenin and the 
Hedgehog (Hh) pathway interact in various cell types while eliciting opposing or 
synergistic cellular effects (see 1.3.3.3). Previous studies showed that Wnt/β-Catenin 
activation is able to inhibit the Shh-driven proliferation of cerebellar granule neuron 
precursor cells (CGNPs) (Lorenz et al. 2011) as well as tumor growth in Shh-dependent 
medulloblastoma (Pöschl et al. 2014). Our in vitro analyses in GNPs of SmoM2Fl/+, 
Ctnnb1(ex3)Fl/+  and SmoM2Fl/+ Ctnnb1(ex3)Fl/+ mice could demonstrate that Shh signalling 
Discussion 
 
73 
 
leads to an increase of proliferation, Wnt signalling to a decrease of proliferation, and Wnt 
signalling decreases the proliferation in the increased condition of Shh signalling. Thus, 
the proliferation of Shh-medulloblastoma cells may be blocked through canonical Wnt 
signalling. These results extend previous studies showing inhibitory effects of Wnt3a 
through non-canonical Wnt signalling on GNPs (Anne et al. 2013). Furthermore, we could 
demonstrate that the Wnt target Axin2 is upregulated and the Shh target Gli1 is 
downregulated in GFP+ cells of SmoM2Fl/+Ctnnb1(ex3)Fl/+ GNP cultures. In addition, β-
catenin was identified as a GSK3 substrate: GSK3-mediated phosphorylation triggers β-
catenin destabilization (Peifer et al. 1994, Yost et al. 1996). This finding thus established 
a central role for GSK3 in Wnt/ß-catenin signalling. Studies since then have revealed 
multifaceted roles of this kinase in Wnt signal transduction. Although the detailed 
mechanisms for GSK3 regulation during Wnt signal transduction remain incompletely 
understood, it is clear that Wnt-mediated GSK3 regulation does not utilize the same 
phosphorylation events as in AKT signalling (Yuan et al. 1999, Ding et al. 2000). Recent 
advances indicate that GSK3 also plays a positive role in Wnt signal transduction by 
phosphorylating the Wnt receptors low density lipoprotein receptor-related protein 
(LRP5/6) and provide new mechanisms for the suppression of GSK3 activity by Wnt in β-
catenin stabilization. Furthermore, GSK3 mediates crosstalk between signalling pathways 
and β-catenin-independent downstream signalling from Wnt. Hence, active canonical Wnt 
signalling is a potent inhibitor of the Shh pathway in medulloblastoma. Pharmacologically, 
activation of Wnt/β-catenin signalling can be achieved via inhibition of GSK3β. Cre 
treatment of cerebellar GSK3βFl/Fl GNPs significantly decreased proliferation (Figure 18).  
With the intent of investigating, whether the newly discovered inhibitory effect of Wnt 
over Shh might represent a novel approach in the therapy of Shh-associated 
medulloblastoma, in vitro experiments on medulloblastoma cells were conducted using 
Lithium, a well-known Wnt activator (Stambolic et al. 1996, Lancaster et al. 2011). Results 
showed that Lithium is able to reduce cell viability of CGNPs and medulloblastoma tumor 
cells from Math1-cre::SmoM2Fl/+ and Ptch1+/-  mice in vitro (Figure 19). Therefore, 
considering the encouraging in vitro results, it is possible to propose the hypothesis that 
Wnt activators may represent a valuable therapeutic option for Shh-associated 
medulloblastoma. Further investigations adopting different dosages of Lithium and other 
Wnt-activating substances appear therefore to be required. 
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4.3 Establishment and characterization of mouse models 
 
Besides the Wnt pathway, there are some other pathways that interact with the SHH 
pathway and components of these pathways may represent venues for further 
investigation, especially in the context of combination therapy with the SHH pathway. P53 
is one of it. In the light of the observation from Kool et al. 2014 that TP53 was enriched in 
pediatric (ages 4-17) MBs, the role of p53 in MB should be examined closely. P53 status is 
important in the prognosis of patients with SHH-medulloblastoma, as well as disease 
incidence. A cohort study suggested that TP53 status plays a critical role in survival status 
of patients, with five-year survival rates differing significantly between 41% and 81%, 
respectively, for SHH-medulloblastoma patients with and without TP53 mutations 
(Zhukova et al. 2013). In this study we tried to develop a tumor model based on MYCN 
amplification and TP53 mutation in cerebellar granule precursors, as this combination 
commonly occurred in the human system at relapse of MB patients (Hill et al. 2015). As 
no tumor development or any other lesions in the brain could be observed (Figure 8), one 
explanation could be that the tumor incidence of our mouse model is so low, that we could 
not detect one tumor, compared to our Math1-creERT2::lsl-SmoM2Fl/+  model, in which 
penetrance was 100%. This suggests that, in general, Cre-mediated excision should be 
sufficient to achieve a tumor penetrance of 100%, but also that MYCN and P53 expression 
may be variable and that a threshold sufficient for tumor development may not be reached 
in tumor-free Math1-creERT2::lsl-Nmyc p53 (homo- and heterozygous) mice. Alternatively, 
additional hits that have not occurred in tumor-free mice may be required for tumor 
development. However, a potential “second hit” could not be identified yet.  
MYC family oncogenes are amplified in ~10% of medulloblastoma tumors and 
amplifications correlates with poor survival (Huse and Holland 2010, Kool et al. 2012, 
Korshunov et al. 2012). MYCN is highly expressed in two of the medulloblastoma 
subgroups (SHH group and Group 4 tumors) (Taylor et al. 2012). To date, however, N-
myc overexpression (alone or in combination with Gli1, IGF-II, or Bcl-2) has failed to 
initiate MB in any experimental model (Browd et al. 2006, McCall et al. 2007). 
Interestingly, a model of MB where murine-derived allografted cells are implanted into 
Discussion 
 
75 
 
nude mice could be developed (Cage et al. 2015). Since PI3K stabilizes MYCN, PI3K 
inhibitors were used to drive degradation. It could be shown that these inhibitors can 
drive apoptosis in MYCN-driven cancers. 
PI3K/AKT signalling is also shown to crosstalk with Hh signalling. The activity of Gli1 is 
crucial determined by its protein stability and localization. Several kinases were known 
to modulate Gli1 protein stability and localization. Treatment of melanoma cells with 
AKT1 inhibitors decreased the number of cells with nuclear Gli1 labelling, while 
increasing the number of cells with cytoplasmic Gli1 labelling, suggesting that AKT1 may 
be required for Gli1 nuclear localization and transcriptional activity (Stecca et al. 2007). 
However, as shown in neuroblastoma, Gli1 activity is suppressed by AKT2 which 
phosphorylates GSK3ß, leading to GSK3ß stabilizing the inhibitory SUFU/GLI1 complex 
(Paul et al. 2013). As Gli1 represents downstream SHH signalling, it is an attractive target 
for specific SHH mediated MB. Inhibition of its activating kinases or activation of its 
inhibitory kinases can be explored. Here, we combined the already existing and well 
described SHH mouse models Math1-creERT2::lsl-SmoM2Fl/+ (see 3.1.1) and Math1-
creERT2::Ptch1Fl/Fl (see 3.1.3) with a PIK3CA mutation (Math1-creERT2::lsl-SmoM2Fl/+ lsl-
Pik3caFl/+, Math1-creERT2::Ptch1Fl/Fl lsl-Pik3caFl/+ and Math1-creERT2::Ptch1Fl/Fl lsl-
Pik3caFl/Fl mice). To analyse the effect of an acute PIK3CA mutation in the view of 
oncogenic transformation, these inducible tumor models were generated, which enable a 
conditional activation of the Shh pathway in postnatal granule cell precursors and a 
simultaneous constitutive activated form of PIK3CA. The additional PIK3CA mutation 
shows an increase in proliferation, leads to a faster tumor development and therefore a 
significantly worse survival prognosis (Figure 6, Figure 7). Hh and PI3K signalling appear 
to synergize in promoting proliferation of cerebellar neuronal precursors and the 
formation of medulloblastoma tumors. Furthermore, looking at the localization of the 
Math1-creERT2::lsl-SmoM2Fl/+ lsl-Pik3caFl/+ tumors it was striking that 13/18 (~72%) had 
contact to the brainstem. For further analysis it would be interesting if these tumors grow 
into the brainstem or also develop out of it. These newly developed mouse models can be 
used for further analysis, e.g treatment studies. 
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4.4 LDE225 treatment of Shh-associated mouse models 
 
Inhibition of the Hh pathway is considered as promising therapeutic avenue and small-
molecule Hh inhibitors are currently evaluated in early clinical trials for Hh-driven 
cancers (Low and de Sauvage 2010, Amakye et al. 2013). Hh-driven childhood tumors 
besides MB are rhabdomyosarcoma (RMS) and rhabdoid tumors (RTs). SMO inhibitors 
are the leading Hh inhibitors in clinical development, examples are LDE225 and 
Vismodegib. The remarkable clinical response of a patient with MB to Vismodegib 
emphasizes the great potential of targeting the Hh pathway in Hh-driven pediatric cancers 
(Rudin et al. 2009). Based on this proof-of-concept, a phase I/II clinical trial with the SMO 
inhibitor LDE225 in pediatric advanced solid cancers has been launched (Geoerger et al. 
2012). So far, LDE225 turned out to be well-tolerated and clinical responses were 
observed in patients with documented Hh activation. Recently, a phase III clinical trial 
with LDE225 in MB has been launched (www.clinicaltrials.gov). 
Although a patient with Hh-driven MB initially showed a remarkable response to the SMO 
inhibitor Vismodegib (Rudin et al. 2009), persistent therapy rapidly led to acquired 
resistance (Yauch et al. 2009). This indicates that, like other targeted therapies, secondary 
resistance to SMO inhibitors is a potential hurdle to durable responses in the clinic. In the 
context of resistance to kinase inhibitors, the elucidation of mechanisms of resistance has 
enormously accelerated the design of alternative strategies to avoid or overcome 
resistance. Thus, a better understanding of the molecular mechanisms of resistance 
against Hh inhibitors is a top priority.  
Several other substances for the treatment of MB have already been analysed. 
Cyclopamine suppresses MB development in Ptch1+/- mice (Sanchez and Ruiz i Altaba 
2005). Unfortunately, cyclopamine is not proper for clinical development because of its 
low oral solubility (Lipinski et al. 2008). More SMO inhibitors are currently being 
evaluated, including vismodegib (GDC-0449), sonidegib (LDE225), BMS-833923, PF-
04449913 and LY2940680, in clinical trials in advanced cancers (Amakye et al. 2013). 
Among these, vismodegib became the first U.S. Food and Drug Administration (FDA) 
approved SMO antagonist for the treatment of advanced or metastatic BCC in 2012 
(Fellner 2012). Vismodegib significantly lessens the rate of appearance of new BCCs in 
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patients (Sekulic et al. 2012). Nonetheless, reports showed that most BCCs regrow after 
vismodegib is stopped (Tang et al. 2012).  
GANT61 and HPI-1 are potential therapeutics for MB that target the Hh signalling 
pathway; both target Gli1 and Gli2 (Lauth et al. 2007, Hyman et al. 2009, Mazumdar et al. 
2011). Recent evidence has shown that ATO can inhibit the Hh pathway via mechanisms 
distinct from that of SMO inhibitors via inhibition of GLI proteins, i. e. by blocking ciliary 
accumulation of GLI2 and by direct binding and inhibition of GLI1/2 proteins (Kim et al. 
2010, Beauchamp et al. 2011). Thus, ATO, a Food and Drug administration (FDA)-
approved drug for the treatment of acute promyelocytic leukemia, may offer an 
alternative treatment option to overcome resistance to SMO inhibitors. Indeed, ATO was 
recently shown in preclinical models to retain antitumor activity in SMO inhibitor-
refractory tumors (Kim et al. 2013). Since concomitant perturbations in additional 
pathways, which interact with Hh signalling or which become activated as compensatory 
mechanisms, have been reported in Hh inhibitor-resistant cases, rational drug 
combinations have been suggested, including PI3K/AKT/mTOR or RAS/MEK/ERK 
inhibitors or epigentically acting drugs (Stecca et al. 2007, Buonamici et al. 2010, Wang et 
al. 2012, Filbin et al. 2013). 
LDE225, BMS-833923 and saridegib target SMO (Buonamici et al. 2010, Lee et al. 2012, 
Lin and Matsui 2012). Here we used LDE225 for the treatment of our Shh-associated 
mouse models. 
Several Smo antagonists including LDE225 are currently being evaluated in clinical trials 
in patients with advanced solid tumors including medulloblastoma (Tremblay et al. 
2009). However, acquired resistance has emerged as a challenge to targeted therapeutics 
and may limit their anti-cancer efficacy (Engelman and Settleman 2008). Indeed, evidence 
of resistance to Smo inhibition has recently been reported in a medulloblastoma patient 
who progressed during therapy with the Smo antagonist GDC0449 (Rudin et al. 2009). 
Here, mouse strains with an activation of the Shh pathway - Math1-creERT2::lsl-SmoM2Fl/+, 
Math1-creERT2::lsl-SmoM2Fl/+ lsl-Pik3caFl/+, and Math1-creERT2::Ptch1Fl/Fl - were treated 
with LDE225 (Figure 21, Figure 23, Figure 24). In both mouse strains with only one 
mutation (Math1-creERT2::lsl-SmoM2Fl/+ and Math1-creERT2::Ptch1Fl/Fl) LDE225 treatment 
led to a significant better survival rate and to a decrease of proliferation of the tumor. 
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Finally these mice died of tumor symptoms anyway. Here we suggest that after the 3-week 
long treatment phase, tumor cells of Math1-creERT2::lsl-SmoM2Fl/+ and Math1-
creERT2::Ptch1Fl/Fl mice developed resistance mechanisms. It is conceivable that genetic 
alterations (mutations, copy-number changes) or changes in gene expression profile 
appeared after the drug treatment that could explain the acquired resistance. Current 
evidence suggests that treatment response to SMO inhibitors may only be transient, while 
resistance rapidly emerges (Kool et al. 2014). Some initially responsive tumors may also 
acquire secondary resistance to treatment, whereas other patients keep in remission for 
several years on a single targeted drug. This indicates that, like other targeted therapies, 
secondary resistance to SMO inhibitors is a potential hurdle to durable responses in the 
clinic. 
Whereas the additional PIK3CA mutation in Math1-creERT2::lsl-SmoM2Fl/+ lsl-Pik3caFl/+ 
mice led to an inhibition of the positive effect of LDE225 treatment. The Smo inhibiton 
effect of LDE225 is here not enough. The survival prognosis for LDE225 treated Math1-
creERT2::lsl-SmoM2Fl/+ lsl-Pik3caFl/+ mice does not differ compared to the control group. 
This upregulation of PI3K signalling could be a mechanism to evade Smo inhibition. 
Therefore a combination therapy of this Smo inhibitor and an additional PI3K/Tor 
inhibitor would be useful. A recent study demonstrated that Igf2, through PI3K signalling, 
potentiates Gli activation induced by low levels of Hh ligand (Riobo et al. 2006). It is 
possible that under conditions of continuous Hh pathway inhibition, the PI3K pathway 
compensates for the loss of Hh signalling and thus becomes a major mediator of resistant 
tumor growth. A combination of the selective PI3K inhibitor BKM120 (also known as 
Buparlisib), which is already used in clinical trials, and LDE225 constitutes a potential 
strategy to delay or prevent resistance to Smo antagonists and has important implications 
for future treatment strategies in medulloblastoma and also other Smo-dependant human 
cancers. 
Interestingly, the earlier treatment start at P20 in Math1-creERT2::lsl-SmoM2Fl/+ lsl-
Pik3caFl/+ mice led to a significant better survival prognosis compared to the later treated 
mice which started at P30 (Figure 23 a). This concludes how important it is to start 
treatment of tumor as soon as possible. It is conceivable that an even earlier starting point 
can lead to an even better prognosis. 
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For future experiments it is planned that the mouse models which were treated with 
LDE225 (Math1-creERT2::lsl-SmoM2Fl/+, Math1-creERT2::lsl-SmoM2Fl/+ lsl-Pik3caFl/+, and 
Math1-creERT2::Ptch1Fl/Fl mice) will be molecularly analysed in detail. These molecular 
analyses include whole exome sequencing of tumor DNA and low-coverage WGS of tumor 
DNA. All samples will be analysed by the mentioned methods before any drug treatment 
in order to fully characterize these models and identify mutations and copy-number 
aberrations that could explain any primary drug resistance present in the tumors at the 
time of biopsy. After drug treatment we will sequence and profile those tumors that 
became resistant to drug treatment to see whether any genetic alterations (mutations, 
copy-number changes) or changes in gene expression profiles will appear that could 
explain the acquired resistance. 
Smoothened inhibitors are now available clinically to treat medulloblastoma. However, 
resistance to these inhibitors rapidly develops thereby limiting their efficacy. The 
determination of Smoothened crystal structures enables structure-based discovery of 
new ligands with new chemotypes that will be critical to combat resistance. In a current 
study 3.2 million available, lead-like molecules against Smoothened were docked, looking 
for those with high physical complementarity to its structure; this represents the first 
such campaign against the class Frizzled G-protein coupled receptor family. Twenty-one 
high-ranking compounds were selected for experimental testing, and four, representing 
three different chemotypes, were identified to antagonize Smoothened with IC50 values 
better than 50 μM. A screen for analogs revealed another six molecules, with IC50 values 
in the low micromolar range (Lacroix et al. 2016). Importantly, one of the most active of 
the new antagonists continued to be efficacious at the D473H mutant of Smoothened, 
which confers clinical resistance to the antagonist vismodegib in cancer treatment. 
In light of recent literature, several considerations are important for future therapeutic 
development for SHH MB. The first consideration is the variable genetic backgrounds of 
SHH-MB in infants, children and adults. For example, patients with mutations upstream 
in the SHH pathway (SHH amplifications, PTCH1 and SMO mutations) in general may 
respond more favourably to SMO inhibitors, while those with mutations downstream 
(GLI2 mutations) may be more resistant to treatment (Kool et al. 2014). The second is the 
development of resistance. An understanding of the radiation and chemotherapy 
resistance mechanisms of MB is necessary for efficient targeting of medulloblastoma. 
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Assessing the influence of crosstalk from other signalling pathways will significantly 
contribute to novel therapeutics for MB with regard to combination therapeutics.  
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4.5 Perspectives  
 
Currently, the selection of patients with MB that qualify for the clinical trial with the SMO 
inhibitor LDE225 is based on a five gene signature that indicates Hh pathway activation 
(Weller et al. 2013). However, this diagnostic test will not be sufficient to identify LDE225-
responsive patients, since it cannot distinguish between different aberrations causing Hh 
activation, e. g. between PTCH1 mutation and GLI1/2 amplification. The innovation of our 
collaborative project resides in the development of more precise molecular diagnostic 
tests that not only detect global activation of the Hh pathway, but also allow for the precise 
definition of the underlying genetic alterations in each individual tumor. This will enable 
the robust pre-therapeutic stratification of patients for the most suitable Hh inhibitor. In 
the long-term perspective, these diagnostic assays will be exploited for patient selection 
in ongoing and future clinical trials with Hh inhibitors for precision oncology.  
As just tumors with downstream mutations may be more resistant to treatment, these 
mutations should be further investigated in mouse studies. One further mouse model 
which should be developed for future studies carries a GLI2 mutation or the combination 
of GLI2 amplifications and TP53 mutations, as this was found to occur in children (ages 4-
17) (Kool et al. 2014). This model should be characterized in detail and used for treatment 
studies with ATO and/or GANT61. 
In addition to the GEMMs, the antitumor activity of Hh inhibitors in relevant preclinical 
models including PDX (patient-derived xenograft; human SHH-MB) models could be 
analysed in parallel with molecular characterization of the corresponding human tumor 
samples, the results of the project will provide novel insights into which molecular 
aberrations causing Hh activation are amenable to which type of Hh pathway inhibitor. 
Depending on the drug responses using single drugs and the molecular alterations 
identified in these treated tumors, the experiments will be repeated and rational drug 
combinations will be used to see whether the induced drug resistance can be prevented. 
The studies in PDX models will be corroborated by our studies in GEMMs with defined 
aberrations of the Hh signalling pathway. Since more and more Hh inhibitors are being 
developed to block Hh signalling at distinct levels of the pathway and since more and more 
molecular lesions are being identified that cause aberrant Hh activation in human cancers, 
the challenge is to precisely tailor the most suitable Hh inhibitor to the individual patient’s 
tumor aberrations. For example, patients harboring Smoothened (SMO) mutation will 
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likely respond to SMO inhibitors, while patients exhibiting GLI2 amplification are 
expected to benefit from GLI inhibitors. The results of our preclinical studies will be 
translated into the ongoing and future clinical trials with Hh inhibitors in children. Since 
the development of rationally targeted cancer therapeutics requires a full understanding 
of the pharmacokinetic/pharmacodynamics (PK/PD) relationship of the investigational 
agents, we will also utilize the preclinical models of Hh pathway activation to correlate Hh 
inhibitor levels in the plasma with pathway inhibition and with antitumor effects. The 
results of these preclinical PK/PD studies will provide useful PK exposure targets as well 
as PD endpoints that can be used as gates for further clinical development. 
By elucidating primary and acquired resistance mechanisms to SMO inhibitors, which are 
currently the leading Hh inhibitors under clinical evaluation, the results of the project will 
pave the way for novel therapeutic strategies to overcome resistance or, alternatively, to 
avoid resistance by dispatching tumors before they become refractory. For example, 
GLI1/2 inhibitors such as arsenic trioxide (ATO) may offer an alternative treatment 
option for cases that are refractory to SMO inhibitors, e.g. due to GLI2 amplification. 
Another example is the design of combination therapies to concomitantly block 
compensatory pathways that become activated upon acquired resistance to SMO 
inhibitors, e.g. by using PI3K/AKT/mTOR inhibitors. Thus, the results of this project will 
contribute to the development of alternative treatment strategies for Hh inhibitor-
resistant patients in many ways, i.e. 1) by discovering the different molecular lesions that 
cause Hh activation in primary tumor samples, 2) by identifying the mechanism of 
resistance to Hh inhibitors in PDX models and GEMMs and 3) by evaluating alternative 
treatment options in refractory mouse models to either circumvent resistance or to avoid 
the emergence of resistance by pre-emptively treating with a combination. The results of 
these studies will be translated into the ongoing and future clinical trials with Hh 
inhibitors in children to design alternative treatment options for patients with primary or 
acquired resistance to Hh inhibitors. Furthermore, the understanding of common escape 
mechanisms will help to develop new diagnostics to prescreen patients for the enrolment 
into clinical trials with Hh inhibitors. 
All GEMMs and PDX models will be molecularly characterized by whole exome 
sequencing, low-coverage WGS (whole genome sequencing), and DNA methylation and 
gene expression profiling. Tumors that become resistant to Hh pathway inhibition will 
again be molecularly characterized by sequencing and profiling and data will be compared 
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to the untreated/vehicle-treated tumors to identify the molecular mechanism(s) of 
acquired resistance. Based on these molecular findings, rational combination treatments 
will be used including drugs targeting other pathways co-operating with Hh signalling.  
All data generated with the mouse models will be compared with molecular data which 
are currently generated from clinical SHH-MB samples treated with LDE225, the SMO 
inhibitor that is being used in a phase III clinical trial in Germany embedded in the overall 
HIT-REZ concept which promotes early clinical trials and therapy optimization studies for 
children and young adults with recurrent MB and ependymoma. Our increased 
understanding of primary and secondary resistance mechanism in SHH-MB will form a 
basis not only for rational combination therapies for primary and relapsed SHH-MB 
tumors, but also for the development of second-generation Hh inhibitors and for the 
development of diagnostic tests that can be applied in a clinical setting to predict which 
patients will be responsive to which drugs. 
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6 Appendix 
6.1 Supplementary Figures 
 
 
 
Figure 25 H&E staining of human (a) and mice (b-f) tumors. Comparison of the morphology of murine 
tumors with different genotypes to each other and to human SHH-MB. All tumors display classic 
morphology (small, blue, round cells). Scale bars 20 µm. 
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Figure 26 Reduced growth of Shh-medulloblastoma after activation of the Wnt-pathway. H&E stains of 
sagittal cerebellar sections. Activation of the Shh-pathway in Math1-positive cerebellar GNPs resulted in a 
thickened EGL at P0 and the formation of medulloblastoma that were readily detectable at P2 (Math1-
cre::SmoM2Fl/+ genotype). Co-activation of the Wnt/β-catenin-signalling-pathway (Math1-
cre::SmoM2Fl/+Ctnnb1(ex3)Fl/+ mice) notably reduced growth of medulloblastoma and led to a decreased 
cerebellar size when compared to Math1-cre controls. Adequate cerebellar layering was not seen (see inset 
with higher magnification). EGL: external granule cell layer, ML: molecular layer, PL: Purkinje cell layer, IGL: 
internal granule cell layer 
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6.4 List of Abbreviations 
 
(C)GNP  (cerebellar) granule neuron precursor 
µg microgram 
µl microliter 
µM micro-molar 
BrdU bromodesoxyuridine 
C57/Bl6 C57 black 6; common inbred strain of laboratory mouse. 
cDNA complementary DNA 
CNS central nervous system 
cre cyclization recombinase or causes recombination 
CSF cerebrospinal fluid 
DNA deoxyribonucleic acid 
E embryonic day 
EGF epidermal growth factor 
EGL external granular layer 
ETMRs embryonal tumors with multi-layered rosettes 
FACS fluorescnence-actiated cell sorting 
FAP Familiary Adenomatous Polyposis 
FGF fibroblast growth factor 
Fl/+ heterozygous for a „floxed“ allele 
Fl/Fl homozygous for a „floxed“ allele 
FVB friend virus B 
Fw forward 
Fz frizzled receptor 
gDNA genomic DNA 
GEMM genetically engineered mouse model 
GL261 glioma cell line 
h hour 
H&E hematoxylin and eosin 
Hek Human embryonal kidney 
HEK 293T human embryonic kidney cells 
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i.p. intraperitoneal 
IGL inner granular layer 
IRES internal ribosome entry site 
IVC individually ventilated cages 
LCA large cell/anaplastic 
LiCl lithium chloride 
loxP locus of X-over P1 
lsl lox stop lox 
MB medulloblastoma  
min minute 
ML molecular layer  
ml milliliter  
mM milli-molar 
MRI magnetic resonance imaging 
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
NeuN neuronal nuclei 
OD optical density 
P postnatal day 
PCL purkinje cell layer 
PCR polymerase chain reaction 
Pen/Strep Penicillin/Streptomycin 
PLO poly-L-ornithine 
PNETs primitive neuroectodermal tumors 
qRT-PCR quantitative real-time PCR 
RCAS replication competent ASLV long terminal repeat with Splice 
acceptor 
RL rhombic lip 
RNA ribonucleic acid 
rpm revolutions per minute 
RT Room temperature 
RU49 zinc finger transcription factor 
Rv reverse 
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sec second 
Shh/SHH sonic hedgehog  
S-phase synthesis phase 
Tam Tamoxifen 
TVA avian retrovirus receptor 
U unit 
UW473 medulloblastoma cell line 
WGS whole genome sequencing 
WHO World Health Organization 
Wnt/WNT The name Wnt is a portmanteau of int (=proto-oncogene 
„integration1“) and Wg (Drosophila gene „wingless“) and stands 
for "Wingless-related integration site" 
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6.5 Gene names and definition of gene symbols 
 
Gene symbols written in capital letters indicate human or mouse protein (e.g. MYC) 
Gene symbols written in italic capital letters indicate human or mouse gene (e.g. MYC) 
 
Gene symbol Gene name in full 
AKT protein kinase B 
APC adenomatous polyposis coli 
ATOH1/MATH1 Protein atonal homolog 1 
BMP-4 Bone morphogenetic protein 4 
CBP/CREBBP CREB-binding protein 
CD44 CD44 molecule (Indian blood group) 
CDK6 cyclin-dependent kinase 6 
CK1 casein kinase 1 
CTNNB1 ß-catenin 
DKK1 dickkopf-related protein 1 
Dvl dishevelled 
EZH2 enhancer of zeste homolog 2 
GFP green fluorescent protein 
GLI1 GLI family zinc finger 1 
GLI2 GLI family zinc finger 2 
GLI3 GLI family zinc finger 3 
GSK3ß Glycogen synthase kinase 3 ß 
hGFAP human glial fibrillary acidic protein 
HOXA2 homeobox A2 
KDM6A lysine (K)-specific demethylase 6A 
Lac Z beta-D-galactosidase 
LRP low-density lipoprotein receptor-related protein 
MLL2/3 myeloid/lymphoid or mixed-lineage leukemia protein 2/3 
MYC (C-MYC) myelocytomatosis viral oncogene homolog (avian) 
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MYCN myelocytomatosis viral related oncogene, neuroblastoma 
derived (avian) 
OTX2 orthodenticle homeobox 2 
p18-Ink4c cyclin-dependent kinase 4 inhibitor C 
p27-Kip cyclin-dependent kinase inhibitor 1B 
p53 (TP53) tumor protein p53 
PIK3CA phosphatidylinositol-4,5-bisphosphate3-kinase catalytic 
subunit alpha 
PTCH1 patched 1 
SFRP1 secreted frizzled-related protein 1 
SMO smoothened, frizzled family receptor 
SNCAIP synuclein alpha interacting protein 
ß2M beta-2-microglobulin 
SUFU suppressor-of-fused 
TCF/LEF transcription factor/lymphoid enhancer-binding factor 
YFP yellow fluorescent protein  
ZMYM3 zinc finger MYM-type containing 3 
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